|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
REVIEW ARTICLE
From the Ottawa Hospital Research Institute and the
Division of Infectious Diseases, Ottawa Hospital, Ottawa, Ontario,
Canada; Department of Immunology/Microbiology, Rush Medical College,
Chicago, IL; and Immunex Corporation, Seattle, WA.
Infection with the human immunodeficiency virus (HIV) is associated
with a progressive decrease in CD4 T-cell number and a consequent
impairment in host immune defenses. Analysis of T cells from patients
infected with HIV, or of T cells infected in vitro with HIV,
demonstrates a significant fraction of both infected and uninfected
cells dying by apoptosis. The many mechanisms that contribute to
HIV-associated lymphocyte apoptosis include chronic immunologic
activation; gp120/160 ligation of the CD4 receptor; enhanced
production of cytotoxic ligands or viral proteins by monocytes,
macrophages, B cells, and CD8 T cells from HIV-infected patients that
kill uninfected CD4 T cells; and direct infection of target cells by
HIV, resulting in apoptosis. Although HIV infection results in T-cell
apoptosis, under some circumstances HIV infection of resting T cells or
macrophages does not result in apoptosis; this may be a critical step
in the development of viral reservoirs. Recent therapies for HIV
effectively reduce lymphoid and peripheral T-cell apoptosis, reduce
viral replication, and enhance cellular immune competence; however,
they do not alter viral reservoirs. Further understanding the
regulation of apoptosis in HIV disease is required to develop novel
immune-based therapies aimed at modifying HIV-induced apoptosis to the
benefit of patients infected with HIV.
(Blood. 2000;96:2951-2964) Patients infected with the human immunodeficiency
virus (HIV) experience a progressive decline in CD4 T-cell number,
resulting in immunodeficiency and increased susceptibility to
opportunistic infections and malignancies. Although CD4 T-cell
production is impaired in patients infected with HIV,1
there is now overwhelming evidence that the primary basis of T-cell
depletion in patients infected with HIV is increased apoptosis of CD4
and CD8 T cells. Since it was first proposed as a potential mechanism
of CD4 T-cell depletion in patients infected with HIV,2
apoptosis and its dysregulation after HIV infection has become a major
focus of research. Although apoptosis may result from the effects of
continuous immune activation that occurs in HIV-infected patients,
considerable data indicate that there are additional distinct
mechanisms by which HIV (and HIV-specific proteins) enhances apoptosis.
Importantly, only a minor fraction of apoptotic lymphocytes are
physically infected by HIV, indicating that the enhanced apoptosis of
lymphocytes seen in infected persons results from mechanism(s) other
than direct infection. Thus, understanding of the mechanisms of
HIV-associated lymphocyte apoptosis may lead to new and more effective
therapies for HIV disease and acquired immunodeficiency syndrome.
Chronic uncontrolled infections provide continuous antigenic
stimulation that causes persistent immune activation and consequent apoptosis. This is the mechanism by which infectious diseases, such as
cytomegalovirus, cause enhanced apoptosis and lymphopenia. Chronic HIV
infection provides a chronic immunologic stimulus; however, it may be
unique in its ability to induce lymphocyte apoptosis through direct or
indirect mechanism(s) that are distinct from immune activation alone.
Although numerous pathogenic viruses have developed mechanisms to
prevent apoptosis of host cells, no such antiapoptotic machinery is
present in HIV. Indeed, HIV-encoded proteins may induce apoptosis of
infected cells and uninfected cells (ie, paracrine death) through
various mechanisms, some of which are defined; others are as yet
unidentified (Table 1).
Apoptosis is a highly regulated and coordinated cellular death
process that is essential for cellular homeostasis. Alterations in the
regulation of apoptosis may lead to malignancies,3
immunodeficiencies,4 and autoimmune
phenomena.5
Apoptosis regulatory proteins
In addition to receptor-mediated apoptosis, other stimuli (eg,
chemotherapy, ultraviolet radiation, and ionizing radiation) induce
changes in mitochondria that include opening of the permeability transition pore and loss of mitochondrial inner transmembrane potential, which allows the release of apoptosis regulatory proteins (including cytochrome c, Apaf-1, and caspase 9)29-32 that
initiate further caspase activation, ultimately leading to apoptosis.
Although classical Fas-induced apoptosis (see above) involves direct
caspase activation without mitochondrial involvement (type 1), in
certain cell types Fas-induced apoptosis may also require mitochondrial activation (type 2).7
Antiapoptosis regulatory molecules
Bcl2 and related family members,38,39 including BclXS, BclXL, Bad, and Bax, influence apoptosis by regulating the intracellular signals that induce apoptosis. Some family members (Bcl2) are antiapoptotic, whereas others (Bax) are proapoptotic. Cells that contain a predominance of proapoptotic Bcl2 family molecules promote apoptosis, and cells with a predominance of antiapoptotic Bcl2 family proteins are relatively apoptosis resistant. Bcl2 consistently blocks apoptosis induced by anticancer and nitric oxide,41 and these effects may result from the inhibition of calcineurin activation,40,42,43 NFAT activation,40 or transcription of Fas ligand.40 Conversely, reports on the effects of Bcl2 on Fas-induced apoptosis are conflicting: Bcl2 may variably inhibit44 or not inhibit45 Fas-induced death. Because members of the Bcl2 family are principally localized within mitochondria, their influence may be greatest in forms of apoptosis that are associated with mitochondrial activation. Thus, Bcl2 overexpression may not inhibit death receptor-initiated apoptosis in cells with a type 1 (mitochondria-independent) Fas pathway, but it may block Fas-initiated death in type 2 (mitochondria-dependent) cells.46 Physiologic T-cell apoptosis Healthy subjects orchestrate a physiologic immune response to a foreign antigen by T-cell activation and proliferation. If this T-cell proliferative response were not regulated, each encounter with a foreign antigen would lead to unending T-cell expansion. Down-regulation of T-cell proliferation occurs by an apoptotic program that is initiated after activation47 (Figure 2, top). After T-cell activation, c-FLIP expression is reduced, and the cells become susceptible to Fas ligation and to caspase 8-mediated apoptosis.33 Exposure to a second activation stimulus (eg, CD3 stimulation in the absence of CD28 costimulation) promotes de novo production of FasL, leading to both autocrine and paracrine Fas/FasL-mediated T-cell apoptosis.48-52 It is important to note that not all physiologic T-cell apoptosis is regulated solely by Fas/FasL interactions; Fas-deficient cells maintain T-cell receptor (CD3)-induced apoptosis that is inhibited by TNF antagonists.53,54
As noted, apoptosis is characterized by distinct morphologic and
biochemical changes, including chromatin condensation, shrinkage of the
cytoplasm, membrane blebbing, and formation of apoptotic bodies.
Apoptosis is a complex and sequential process, and, as such, some
assays detect changes that occur early, whereas other assays detect
later events. The most common assays used in the detection of apoptosis
are listed in Table 255-99;
many have been used to evaluate apoptosis in patients infected with
HIV. In a direct comparison of the relative benefits of these assays
for use in the evaluation of apoptosis of HIV-infected patients, TUNEL staining was the most specific and therefore may be the most accurate assay to use in this patient population.100
Cells obtained from HIV-infected patients and cells infected with HIV in vitro show changes in the regulation of Fas and Fas ligand (reviewed in101). Acute HIV infection of the promonocytic cell line U937 is associated with viral replication-dependent apoptosis102 that is characterized by the increased membrane expression of Fas102 and FasL,102 by the down-regulation of antiapoptotic proteins Bcl2 and BclXL,103,104 and by a concomitant increase in proapoptotic BclXS and Bax.103,104 The hypothesis that Fas/FasL interactions may be responsible for HIV-induced apoptosis is supported by the observation that soluble Fas receptor decoys block HIV-associated death in U937 cells.102 This is in marked contrast to the effects of acute HIV infection of T-cell lines, which is Fas independent despite increased Fas expression.105-108 Interestingly, though T cells from HIV-infected patients have altered expression of Bcl2, the expression of Bax, BclXL, and BclXS does not differ from that of uninfected controls.109 T cells from HIV-infected patients exhibit both increased Fas receptor expression and enhanced susceptibility to Fas-mediated death.110-117 FasL is elevated in peripheral blood mononuclear cells (which contain monocytes)114,118,119 from HIV-infected patients, and the plasma level of soluble FasL is increased in HIV-positive patients and correlates with HIV RNA burden.120 The demonstrated increases in Fas expression, Fas susceptibility, and Fas ligand expression suggest that these molecules may be important in some forms (see below) of HIV-induced cell death, though direct T-cell killing is independent of Fas.105-108 Intracellular levels of c-FLIP in resting cells from HIV-negative
patients decrease after activation, resulting in enhanced sensitivity
to Fas-mediated apoptosis.33 This observation, coupled with observations that apoptosis in patients infected with HIV occurs
in activated CD45 RO+, HLA-DR+,
CD28 The regulation of TNF, TNF receptors, or both is fundamentally altered in HIV-infected patients.126-129 Both cognate receptors for TNF, p75 TNFR and p55 TNFR,130 are expressed in a variety of cell types. However, only ligation of the p55 TNF receptor leads to apoptosis.16,17,53,131,132 Elevated serum TNF levels are seen in symptomatic HIV-infected patients126-129 but not in asymptomatic patients.133,134 Furthermore, (1) HIV infection of lymphocytes or monocytes results in TNF production,135,136 and (2) TNF activates the transcription factor NFkB, which, in turn, activates HIV transcription,137,138 initiating an autocrine loop that results in high levels of TNF production and increased levels of HIV transcription. In addition, elevated serum levels of soluble p75 TNFR are predictive of HIV disease progression, independent of other immunologic or virologic prognostic markers.139 Although little is known of the ability of TNF to induce apoptosis in HIV-infected cells, HIV-infected macrophage-mediated killing of uninfected CD4 T-cell blasts (see below) can be partially reduced by the administration of soluble TNFR decoys,40 and TNF may contribute to apoptosis induced by gp120-mediated cross-linking of CD4138 (see below). The potential role of TNF as a mediator of HIV disease has prompted trials of anti-TNF therapy to retard HIV disease progression. Thalidomide reduces TNF secretion,141 and pentoxifylline reduces TNF mRNA half-life.138 However, clinical trials with each of these agents have consistently failed to show improvement in either immunologic or virologic outcomes.142-144 Other studies using soluble TNF antagonists have had similarly disappointing results.145 There is also relatively little information concerning the potential role of TRAIL/APO 2-L in apoptosis in HIV-infected patients. Current data suggest that TRAIL/APO 2-L can bind to 1 of 5 receptors, TRAIL/APO 2-L-R1, TRAIL/APO 2-L-R2, TRAIL/APO 2-L-R3, TRAIL/APO 2-L-R4,146 and osteoprotegerin.147 Binding of TRAIL/APO 2-L to TRAIL/APO 2-L-R1 or R2 transduces apoptotic signals, whereas binding to TRAIL/APO 2-L-R3 or TRAIL/APO 2-L-R4 does not. The effects of TRAIL/APO 2-L binding to osteoprotegerin are unknown. Although it has been suggested that the relative expression of TRAIL/APO 2-L-R3 and TRAIL/APO 2-L-R4 to TRAIL/APO 2-L-R1 and TRAIL/APO 2-L-R2 influences susceptibility to TRAIL/APO 2-L-mediated killing,148-150 recent studies do not support this hypothesis. Rather, intracellular levels of c-FLIP may correlate with the sensitivity or resistance to TRAIL/APO 2-L-induced apoptosis in target cells.151,152 Although no studies to date have evaluated the relative expression of TRAIL/APO 2-L receptor(s) or TRAIL/APO 2-L expression in patients infected with HIV, it has been observed that (in contrast to cells from HIV-uninfected patients) cells from HIV-infected patients are susceptible to TRAIL/APO 2-L-mediated killing.153 This finding, together with the fact that activation-induced cell death in patients with HIV infection may be partially inhibited using antagonistic TRAIL/APO 2-L-specific antibodies,154 suggests that TRAIL/APO 2-L and TRAIL/APO 2-L receptor dysfunction may contribute to HIV pathogenesis.
HIV infection is associated with enhanced apoptosis in CD4 T cells infected by HIV and in uninfected T cells. In this section we review proposed mechanisms of CD4 T-cell apoptosis, focusing on whether the proposed mechanisms affect infected cells, uninfected cells, or both. Gp120-induced apoptosis Gp120 is an HIV viral envelope glycoprotein that can bind to and cross-link the CD4 receptor and the chemokine coreceptors. Cross-linking of CD4 T cells by gp120 causes the induction of enhanced susceptibility to Fas-mediated killing.155 In previously activated cells, gp120 cross-linking results in apoptosis156 (possibly mediated by IFN- , TNF, or
both157), down-regulation of Bcl-2
expression,158 and activation of caspase
3.159 The apoptotic response to gp 120 is almost
completely inhibited by soluble CD4 and by anti-gp120
antibodies.160 Further evidence for the specificity of
this interaction is provided by the observation that a point mutation
in the V3 loop of gp120 inhibits the induction of apoptosis in CD4 T
cells.161 Finally, this interaction must also involve CD4
signaling because deletion or mutation of the intracytoplasmic portion
of CD4 also abrogates the apoptotic response.162,163
Most of the experiments involving gp120-induced apoptosis evaluate apoptosis that occurs after several days. However, recent reports164-166 show that gp120 cross-linking of CD4 and CXCR4 chemokine receptor results in nonapoptotic death within several hours of stimulation by a mechanism that appears to be independent of p56LCK,164 g-protein-coupled signaling,166 Fas, or TNF receptors.165 The administration of CXCR4 antagonists blocks this apoptosis response to the HIV envelope.167 It is appealing to invoke gp120 as a responsible mechanism for CD4 T-cell death in patients infected with HIV because it does not depend on the infection of all cells that become apoptotic and it does not require the presence of viable virions. Circulating immune complexes and replication-incompetent viruses that contain gp120 can induce death in a similar manner.168-170 Apoptosis induced by other HIV proteins Transfection experiments demonstrate that the ectopic expression of HIV Tat induces apoptosis. Further, gp120/160-deleted HIV maintains its ability to induce infected cell apoptosis, potentially because of the Tat-directed up-regulation of caspase 8171 or because of Fas ligand.172 Importantly, Tat has also been implicated as an inducer of apoptosis in uninfected T cells, potentially by Fas-dependent mechanisms, superoxide dismutase inhibition, or activation of cyclin-dependent kinases.173-175 The ability of Tat to induce uninfected cell death has also been demonstrated in vitro for neurons, lymphocytes, and CD4 T-cell lines. Its clinical relevance is suggested by observations that Tat is readily secreted by infected cells176 and cellular or humoral immunity to Tat may have protective effects against HIV disease progression.177Because Nef is essential for viral pathogenicity, HIV-encoded Nef has been suggested as a potential mediator of apoptosis.178 This proposal is supported by the following findings: (1) human infection with naturally occurring Nef deletion mutants leads to less rapid CD4 T-cell depletion (compared to strains with Nef),179,180 though the differences may be related to the decreased efficiency of viral replication181-184; (2) Nef synergistically enhances the activating effects of T-cell receptor ligation,185-187 though this enhancement may be stimulus dependent187-191; (3) Nef-expressing T cells coexpress FasL,192 as do infected T cells from SIV-infected macaques but not T cells from macaques infected with similar strains of SIV that contain mutations within the Nef gene193 (the mechanism(s) by which Nef results in activation and FasL production remain unclear, yet mutational analysis indicates that the carboxy terminus of the CD4 receptor associates with both Nef and p56LCK194); lastly, (4) Nef may exert an apoptotic effect on uninfected CD4 T cells by binding to unidentified receptor(s),195 resulting in Fas-independent death.196 In this regard, Nef may induce apoptosis of infected and uninfected cells. HIV-encoded vpr also has the ability to induce apoptosis through transfection and exogenous treatment. Proposed mechanisms include the induction of G2/M cell cycle arrest197,198 and a direct effect on mitochondrial permeability.199 Vpr also influences viral LTR transcription,200,201 cellular activation, and differentiation,202,203 suggesting a role in the development of HIV reservoirs. The seeming paradox of inducing apoptosis while promoting viral reservoirs is elucidated by data that vpr may, in certain situations, inhibit apoptosis.204-206 The observation that virion-associated vpr acts as an immediate early viral protein to induce apoptosis207 is inconsistent with the apparent requirement that viral replication must occur before the onset of infected T-cell apoptosis. In addition, the finding that direct HIV-induced T-cell apoptosis occurs in all phases of the cell cycle107 brings into question the role of vpr in direct infection apoptosis. Vpr is more likely to be involved in regulation of latency, control of replication, and resistance to antiretroviral agents.208 Knowledge that HIV-encoded protease is a cytotoxic protein that leads to apoptosis in human and bacterial cells after transfection209-212 has been exploited as a method of screening compounds for potential HIV protease inhibitory activity.213 However, the relevance of HIV protease to HIV-infected T-cell death in vitro and in vivo is unknown. HIV protease expression (by Western blotting) correlates with the presence of apoptosis in vitro and in vivo.214 Further studies demonstrate that HIV protease directly cleaves caspase 8214 and modifies cellular susceptibility to apoptosis by virtue of proteolytic degradation of the antiapoptotic protein Bcl2.215 Together these findings indicate that HIV protease may also play a role in the death of HIV-infected T cells. There are no data to suggest that HIV protease may influence the death of uninfected cells. Indirect mechanisms of HIV-associated apoptosis In addition to apoptosis induced directly by HIV proteins, HIV infection may induce T-cell apoptosis through indirect mechanisms, including activation-induced cell death and autologous infected cell-mediated killing. The indirect mechanisms of T-cell death mediate the deaths principally of uninfected T cells (Figure 2).Activation-induced cell death T cells obtained from HIV-infected patients undergo spontaneous apoptosis at a greater rate than cells from HIV-seronegative subjects.111,216-219 Furthermore, the ex vivo activation of CD4 T cells from HIV-infected patients (using a variety of stimuli) consistently enhances apoptosis compared with cells from uninfected subjects.111,122,124,217-219 This phenomenon, termed activation-induced cell death (AICD), occurs only in cells that have been previously activated,49,52 and it may represent the in vitro model of the effects of repeated antigenic stimulation.49,52,220,221 Naive peripheral blood T cells from HIV-negative patients, when stimulated through the T-cell receptor, undergo proliferation, cytokine secretion,222-226 and the development of susceptibility to apoptosis induced by Fas ligation.48,52,220,221 Subsequent stimulation results in AICD by the de novo production of FasL, which mediates autocrine and paracrine apoptosis.48,52,220,221 Both in vivo and in vitro, HIV infection is associated with an activated T-cell phenotype,227-231 increased expression of Fas, enhanced susceptibility to Fas-mediated killing,111,115,116,174,232,233 and increased T-cell-expressed FasL after T-cell receptor stimulation,114,234 suggesting a role for Fas/FasL in HIV-associated AICD. Findings that retinoic acid inhibits FasL expression and resultant apoptosis in vitro221 and that retinoic acid therapy in HIV-infected patients reduces CD4 T-cell depletion235 support a causal role for Fas/FasL interactions in T-cell death induced by HIV.Elevated levels of apoptosis are seen after mitogenic stimulation or
TCR cross-linking of PBL from HIV-seropositive
patients.124,154,216-218,227,236,237 The molecular signals
responsible for apoptosis in these patients are unclear, but the
administration of Fas, TRAIL/APO 2-L, or TNF antagonists reduces AICD
in cells from patients infected with HIV,154,237
suggesting that all 3 signals Autologous infected cell-mediated killing Macrophages,102,140 monocytes,213,238,239 peripheral blood mononuclear cells,240 CD4 T cells,241 and CD8 T cells242 derived from HIV-infected patients may induce the death of uninfected CD4 T lymphocytes. Autologous infected cell-mediated killing may involve gp120 interactions (see below), the Fas/FasL system, or both. Macrophages express basal levels of FasL that are significantly up-regulated after infection with HIV,102 and monocytes from HIV-infected patients have significantly increased FasL expression compared with monocytes from HIV-negative controls.243 HIV-infected macrophages (and, to a lesser extent, uninfected macrophages) have been shown to kill Fas-sensitive T-cell targets102 in a major histocompatibility complex-unrestricted and Fas/TNF-dependent manner.140 Macrophage-mediated killing appears to be selective for uninfected T cells,244 as opposed to the mechanisms involved in infected T-cell death described above. Macrophage-mediated CD4 T-cell apoptosis has implications in vivo because levels of tissue apoptosis directly correlate with levels of macrophage-associated FasL.245 Thus, FasL may be the mediator of uninfected CD4 T-cell death by monocytes, macrophages,213,239 and CD8 T cells.242,246
Although levels of CD8 T-cell apoptosis are consistently elevated in patients infected with HIV (whether this occurs spontaneously, in response to activation stimuli [AICD] or after coincubation with autologous infected cells102,122-124,154,216,227,240,244,247-249), the CD8 T-cell count is not significantly reduced in these patients. This apparent paradox may be resolved by observations in SIV-infected primates receiving total body irradiation, in which it was observed that CD8 T-cell recovery significantly precedes the recovery of CD4 T cells.250 A similar delay in CD4 repopulation is also seen in humans receiving high-dose chemotherapy.251,252 These data have several potential interpretations, yet they demonstrate that CD8 T-cell rebound occurs earlier than CD4 T-cell rebound after PBL depletion. In HIV-infected patients, it may therefore be expected that if rates of CD4 and CD8 T-cell loss were equal, the steady state CD8 number may be greater than the CD4 number because of the quicker recovery times. Further, HIV-associated apoptosis may lead to greater absolute numbers of CD4 T-cell apoptosis than CD8 T-cell apoptosis, because direct infection and gp120-mediated apoptosis selectively target cells that express CD4, whereas gp120 does not bind to (and thus cross-link) CD8. Nonetheless, it has recently been proposed that macrophage-associated gp120 may mediate CD8 T-cell apoptosis through interaction with CXCR4.253 Alternative potential mechanisms may also be involved (see below). The fact that CD8 T cells from patients with HIV infection are more activated than are similar cells from HIV-uninfected persons227,254-257 suggests that the enhanced state of susceptibility to apoptosis is present in CD8 and in CD4 T cells and that CD8 T cells would be expected to die by apoptosis after exposure to another activation stimulus or with a preformed apoptosis-inducing ligand (eg, macrophage-associated FasL140). Furthermore, CD8 T cells express the CD4 receptor after activation, thereby rendering them susceptible to direct infection by the virus.258,259 In addition, the enhanced expression of CD4 antigen on CD8 T cells would be expected to render these double-positive cells more susceptible to the effects of gp120 cross-linking and subsequent apoptosis. Despite the several possible pathways that may be responsible for CD8 T-cell apoptosis in HIV-infected patients, chronic antigenic stimulation most likely contributes to CD8 T-cell apoptosis. The relative role of direct infection leading to CD8 T cell death remains untested.
Clinical studies in patients infected with HIV measure spontaneous apoptosis, Fas ligation-induced apoptosis, and apoptosis occurring in response to mitogenic activation or TCR cross-linking. In relation to the various mechanisms of apoptosis outlined above, spontaneous apoptosis may reflect infected cell apoptosis or gp120-induced apoptosis; Fas-induced apoptosis may reflect autologous cell-mediated killing of uninfected bystander cells or AICD; apoptosis in response to mitogen or CD3 ligation reflects AICD. In studies in which tissue apoptosis has been measured,260-262 few apoptotic cells are found to be physically infected by virus,260 suggesting that tissue apoptosis reflects the killing of uninfected cells by gp120-induced or autologous cell-mediated killing of uninfected cells. The magnitude of apoptosis observed in HIV-infected patients correlates well with the stage of HIV disease in longitudinal and cross-sectional analyses.263-265 Spontaneous apoptosis is greater in HIV-infected patients with progressive disease than in uninfected patients.266,267 In addition, spontaneous apoptosis in patients with long-term nonprogressive HIV infection are similar to those of HIV-negative patients.268 Thus, the rate of apoptosis correlates inversely with CD4 T-cell depletion. Because recent advances in HIV therapy have resulted in sustained increases in CD4 T cell number, if enhanced apoptosis causes CD4 T-cell depletion then apoptosis must decrease during therapy. Numerous studies have shown that apoptosis in lymph nodes, rectal mucosa, and PBL subsets from patients infected with HIV decreases dramatically in response to protease inhibitor-based HIV treatment.125,269-274 This effect is seen for spontaneous apoptosis, apoptosis in response to T-cell receptor ligation, apoptosis in response to mitogenic stimulation, and apoptosis in response to Fas receptor ligation.125,271,272,274 The decrease in apoptosis is rapid and is seen as early as 4 days after protease inhibitor therapy is initiated125; it occurs in all patients within 14 days.271-274 Because the decrease precedes significant changes in viral replication, it has been suggested that protease inhibitors may be antiapoptotic,275,276 possibly by virtue of inhibiting the activity of effector proteases involved in apoptosis.
One hallmark of infection with HIV is progressive T-helper-cell
dysfunction. As HIV disease progresses, the balance of Th1 cytokines
(IL-2 and IFN- Apoptosis in patients with HIV infection is modulated by exogenous cytokines or cytokine antagonists that promote a Th1 helper cell phenotype and by cytokines that promote T-cell proliferation. IL-2 therapy in patients infected with HIV results in increased CD4 T-cell numbers unrelated to decreases in viral replication. Thus, IL-2 may modulate CD4 T-cell survival directly, possibly through an antiapoptotic mechanism, a hypothesis supported by in vitro studies in which clinically relevant concentrations of IL-2 significantly reduce spontaneous apoptosis in CD4+ T cells from HIV-infected patients but not from HIV-uninfected patients.283 IL-15 is a T-cell growth factor whose effects include T-cell
proliferation, enhanced cytotoxicity of T cells and natural killer cells, B-cell proliferation, and immunoglobulin
secretion.284 The effects of IL-15 on T cells are related
to its ability to bind to a trimeric receptor consisting of the
IL-15R IL-16 is a chemoattractant289 that inhibits lymphocyte activation290 and may also inhibit HIV replication.291 Possibly because of its antiproliferative effects, IL-16 treatment in vitro decreases levels of anti-CD3- or anti-Fas-induced apoptosis in lymphocytes from HIV-infected patients.292 However, the inhibitory effects of IL-16 on apoptosis are not seen in the context of spontaneous apoptosis.292
The institution of highly active antiretroviral therapy (HAART) has witnessed a major impact on immune reconstitution: sustained increases in numbers of circulating CD4 T cells associated with a rapid drop in plasma viral RNA levels. The mechanisms proposed to explain the increase in numbers of CD4 T cells include cellular redistribution from lymphoid tissue,293 cellular proliferation of the peripheral T-cell pool,294 new T-cell synthesis from a thymic source,295,296 and reduced levels of apoptosis (see above). We have previously demonstrated that HAART therapy rapidly reduces apoptosis in lymphoid tissue273 and significantly decreases apoptosis in PBL.125,273 The decrease in apoptosis occurs before significant changes on plasma viral RNA levels and when patients are receiving only the protease inhibitor component of the HAART regimen.125 This finding has led to the proposal that protease inhibitors have an effect on immune reconstitution that is independent of their ability to suppress HIV replication.275,276,297 In vitro therapy with protease inhibitors has been shown to reduce the expression of selected caspases in treated cells and to reduce the rate of caspase 3 activation.275,297 Additional evidence for an indirect protease inhibitor effect comes from studies that demonstrate sustained CD4 rises in patients who experience virologic failure298-301 and who are receiving protease inhibitor-containing HAART regimens. The early rise (2 weeks) in CD4 cells attributable to a reduction in
apoptosis appears to be followed by a phase of CD4 cell increase due to
cellular redistribution and proliferation of predominately memory CD4 T
cells302-306 (Figure 3). A
possible third phase consists mainly of new T-cell synthesis
characterized by cells with a naive phenotype.307 This
third phase of T-cell regeneration is characterized by the presence of
circular DNA elements formed after the rearrangement of possible T-cell
receptor alleles, thereby indicating that these are newly produced T
cells that have matured in the thymus.295,296
If CD4 T-cell depletion in HIV infection results from enhanced apoptosis, then the prevention of apoptosis might be expected to modify the course of HIV disease. In vitro studies using apoptosis inhibitors (with no intrinsic antiviral properties) on PBL from HIV-infected patients cause increased viral production and increased cell survival.308 These findings suggest that non-apoptotic-infected cells serve as viral reservoirs and that it is unlikely that phenotypic and functional abnormalities of infected cells will be reversed by merely inhibiting apoptosis. Thus, blocking apoptosis alone fails to meet 2 objectives of effective HIV therapy: it does not decrease viral replication or decrease viral reservoirs, and it does not increase cellular immune competence. The main obstacle to viral eradication in HIV-infected patients (reviewed in Chun and Fauci309) is the presence of chronically infected latent reservoir cells, such as macrophages, and latently infected CD4 T lymphocytes.310-313 In these cellular populations, HIV infection is not associated with apoptosis but with a chronic productively infected phenotype. Indeed, latently infected CD4 T cells have a markedly prolonged half-life (estimated at 6 months), which limits the probability that viral reservoirs can be eliminated by interference in viral replication alone.314 In fact, recent estimates based on the half-life of latently infected cells suggest that 60 years of viral suppression would be required to eliminate viral reservoirs.311 A possible way to achieve viral eradication is to target infected macrophages and latently infected CD4 T cells to undergo apoptosis after infection. Along these lines, it has recently been proposed that treatment with a pro-caspase 3 analogue, which contains an HIV protease-specific sequence in its prodomain, may cause apoptosis of all infected cells.315 Additional research is required to evaluate the clinical usefulness of this and other approaches designed to enhance the apoptosis of cells that normally function as reservoirs for HIV. The concept of enhancing HIV-associated apoptosis is, however, a potentially significant step forward in attempts to modify apoptosis for the benefit of patients infected with HIV. It further underscores the need for continued efforts to understand the regulation of apoptosis induced by HIV infection.
The authors thank Ms A. Carisse for expert secretarial assistance and the entire Badley laboratory staff and Dr B. W. D. Badley for helpful discussions and manuscript review.
Submitted January 3, 2000; accepted May 10, 2000.
Supported by grants from the Medical Research Council of Canada (HOP-36047) and the Doris Duke Foundation (T98026), the AIDS Program Committee of Ontario, and the Ontario HIV Treatment Network.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Andrew D. Badley, Division of Infectious Diseases, Ottawa Hospital Research Institute, 501 Smyth Rd, Ottawa, Ontario K1H 8L6, Canada; e-mail: abadley{at}ottawahospital.on.ca.
1. Hellerstein MB, Hanley MB, Cesar D, et al. Directly measured kinetics of circulating T lymphocytes in normal and HIV-1-infected humans. Nat Med. 1999;5:83-89[Medline] [Order article via Infotrieve]. 2. Ameison JC, Capron A. Cell dysfunction and depletion in AIDS: the programmed cell death hypothesis. Immunol Today. 1991;12:102-105[Medline] [Order article via Infotrieve]. 3. Benitez-Bribiesca L. Assessment of apoptosis in tumor growth: importance in clinical oncology and cancer therapy. In: Lockshin RA,Zakeri Z,Tilly JL, eds. When Cells Die. New York, NY: Wiley-Liss; 1998:453-476. 4. Laurence J, Mitra D, Steiner M, Lynch DH, Siegal FP, Staiano-Coico L. Apoptotic depletion of CD4+ T cells in idiopathic CD4+ lymphocytopenia. J Clin Invest. 1996;97:672-680[Medline] [Order article via Infotrieve]. 5. Budd RC. Apoptosis in autoimmunity. In: Lockshin RA,Zakeri Z,Tilly JL, eds. When Cells Die. New York, NY: Wiley-Liss; 1998:279-304. 6. Nagata S. Apoptosis by death factor. Cell. 1997;88:355-365[Medline] [Order article via Infotrieve]. 7. Scaffidi C, Fulda S, Srinivasan A, et al. Two CD95 (APO-1/Fas) signaling pathways. EMBO J. 1998;17:1675-1687[Medline] [Order article via Infotrieve]. 8. Darnay BG, Aggarwal BB. Early events in TNF signaling: a story of associations and dissociations. J Leukoc Biol. 1997;61:559-566[Abstract]. 9. Wiley SR, Schooley K, Smolak PJ, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity. 1995;3:673-682[Medline] [Order article via Infotrieve]. 10. Mohler KM, et al. Protection against a lethal dose of endotoxin by an inhibitor of tumor necrosis factor processing. Nature. 1994;370:218-220[Medline] [Order article via Infotrieve]. 11. McGeehan GM, et al. Regulation of tumor necrosis factor: a processing by a metalloproteinase inhibitor. Nature. 1994;370:558-561[Medline] [Order article via Infotrieve]. 12. Tanaka M, Suda T, Haze K, et al. Fas ligand in human serum. Nat Med. 1996;2:317-322[Medline] [Order article via Infotrieve].
13.
Chinnaiyan AM, Tepper CG, Seldin MF, et al.
FADD/MORT1 is a common mediator of CD95 (Fas/APO-1) and tumor necrosis factor receptor-induced apoptosis.
J Biol Chem.
1996;271:4961-4965
14.
Memon SA, Hou J, Moreno MB, Zacharchuk CM.
Apoptosis induced by a chimeric Fas/FLICE receptor: lack of requirement for Fas- or FADD-binding proteins.
J Immunol.
1998;160:2046-2049 15. Zhang J, Cado D, Chen A, Kabra NH, Winoto A. Fas-mediated apoptosis and activation-induced T-cell proliferation are defective in mice lacking FADD/Mort1. Nature. 1998;392:296-300[Medline] [Order article via Infotrieve]. 16. Hsu H, Xiong J, Goeddel DV. The TNF receptor 1-associated protein TRADD signals cell death and NF-k B activation. Cell. 1995;81:495-504[Medline] [Order article via Infotrieve]. 17. Hsu H, Shu H-B, Pan M-G, Goeddel DV. TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways. Cell. 1996;84:299-308[Medline] [Order article via Infotrieve]. 18. Miller DK. The role of the caspase family of cysteine proteases in apoptosis. Immunology. 1997;95:35-49. 19. Stroh C, Schulze-Osthoff K. Death by a thousand cuts: an ever increasing list of caspase substrates. Cell Death Differer. 1998;5:997-1000[Medline] [Order article via Infotrieve]. 20. Cohen GM. Caspases: the executioners of apoptosis. J Biochem. 1997;326:1-16. 21. Muzio M, Chinnaiyan AM, Kischkel FC, et al. FLICE, a novel FADD/homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/APO-1) death-inducing signaling complex. Cell. 1996;85:817-827[Medline] [Order article via Infotrieve].
22.
Scaffidi C, Medema JP, Krammer PH, Peter ME.
FLICE is predominantly expressed as two functionally active isoforms, caspase-8A and caspase-8/b.
J Biol Chem.
1997;272:26953-26958 23. Medema JP, Scaffidi C, Kischek FC, et al. FLICE is activated by association with the CD95 death-inducing signaling complex (DISC). EMBO J. 1997;16:2794-2804[Medline] [Order article via Infotrieve]. 24. Fujita E, Kouroku Y, Miho Y, Tsukahara R, Ishiura S, Momoi T. Wortmannin enhances activation of CPP32 (caspase-3) induced by TNF or anti-Fas. Cell Death Differer. 1998;5:289-297[Medline] [Order article via Infotrieve].
25.
Fernandes-Alnemri T, Armstrong RC, Krebs J, et al.
In vitro activation of CPP32 and Mch3 by Mch4, a novel human apoptotic cysteine protease containing two FAD-like domains.
Proc Natl Acad Sci U S A.
1996;93:7464-7469 26. Kuman S. The apoptotic cysteine protease CPP32. Int J Biochem Cell Biol. 1997;29:393-396[Medline] [Order article via Infotrieve]. 27. Rosen A, Casciola-Rosen L. Macromolecular substrates for the ICE-like proteases during apoptosis. J Cell Biochem. 1997;64:50-54[Medline] [Order article via Infotrieve]. 28. Johnson Webb S, Harrison DJ, Wyllie AH. Apoptosis: an overview of the process and its relevance in disease. In: Kauffman S, ed. Advances in Pharmacology "Apoptosis."; 1997:1-44.
29.
Saleh A, Srinivasula SM, Acharya S, Fishel R, Alnemri ES.
Cytochrome c and dATP-mediated oligomerization of Apaf-1 is a prerequisite for procaspase-9 activation.
J Biol Chem.
1999;274:17941-17945
30.
Bossy-Wetzel E, Green DR.
Caspases induce cytochrome c release from mitochondria by activating cystosolic factors.
J Biol Chem.
1999;274:17484-17490
31.
Narula J, Pandey P, Arbustini E, et al.
Apoptosis in heart failure: release of cytochrome c from mitochondria and activation of caspase-3 in human cardiomyopathy.
Proc Natl Acad Sci U S A.
1999;96:8144-8149
32.
Soengas MS, Alarcon RM, Yoshida H, et al.
Apaf-1 and caspase-9 in p53 dependent apoptosis and tumor inhibition.
Science.
1999;284:156-159 33. Irmler M, Thome M, Hahne M, et al. Inhibition of death receptor signals by cellular FLIP. Nature. 1997;388:190-195[Medline] [Order article via Infotrieve]. 34. Tschopp J, Thome M, Hofmann K, Mein E. The fight of viruses against apoptosis. Curr Opin Gene Devel. 1998;9:82-87. 35. Liston P, Roy N, Tamai K, et al. Suppression of apoptosis in mammalian cells by NAIP and a related family of IAP genes. Nature. 1996;379:349-353[Medline] [Order article via Infotrieve]. 36. Deveraux QL, Takahaashi R, Salvesen GS, Reed JC. X-linked IAP is a direct inhibitor of cell-death proteases. Nature. 1997;388:300-304[Medline] [Order article via Infotrieve]. 37. Duckett CS, Nava VE, Gedrich RW, et al. A conserved family of cellular genes related to the baculovirus iap gene and encoding apoptosis inhibitors. EMBO J. 1996;15:2685-2694[Medline] [Order article via Infotrieve]. 38. Shimizu S, Eguchi Y, Kamiike W, Matsuda H, Tsujimoto Y. Bcl-2 expression prevents activation of the ICE protease caspase. Oncogene. 1996;12:2251-2257[Medline] [Order article via Infotrieve].
39.
Reed JC.
Bcl-2 and the regulation of programmed cell death.
J Cell Biol.
1994;124:1-6
40.
Srivastava RK, Sasaki CY, Hardwick JM, Longo DL.
Bcl-2-mediated drug resistance: inhibition of apoptosis by blocking nuclear factor of activated T lymphocytes (NFAT)-induced Fas ligand transcription.
J Exp Med.
1999;190:253-265
41.
Okuno S, Shimizu S, Ito T, et al.
Bcl-2 Prevents caspase-independent cell death.
J Biol Chem.
1998;273:34272-34277 42. Shibasaki F, Kondo E, Akagi T, McKeon F. Suppression of signalling through transcription factor NF-AT by interactions between calcineurin and Bcl-2. Nature. 1997;386:728-731[Medline] [Order article via Infotrieve].
43.
Wang HG, Pathan N, Ethell IM, et al.
Ca2+ induced apoptosis through calcineurin dephosphorylation.
Science.
1999;284:339-343 44. Itoh N, Tsujimoto Y, Nagata S. Effect of bcl-2 on Fas antigen-mediated cell death. J Immunol. 1993;151:621-627[Abstract]. 45. Chiu VK, Walsh CM, Liu CC, Reed JC, Clark WR. Bcl-2 blocks degranulation but not fas-based cell-mediated cytotoxicity. J Immunol. 1995;154:2023-2032[Abstract].
46.
Scaffidi C, Schmitz I, Zha J, Korsmeyer SJ, Krammer PH, Peter ME.
Differential modulation of apoptosis sensitivity in CD95 type I and type II cells.
J Biol Chem.
1999;274:22532-22538 47. Lenardo M, Chan FK-M, Hornung F, et al. Mature T lymphocyte apoptosis: immune regulation in a dynamic and unpredictable antigenic environment. Annu Rev Immunol. 1999;17:221-253[Medline] [Order article via Infotrieve].
48.
Alderson MR, Tough TW, Davis-Smith T, et al.
Fas ligand mediates activation-induced cell death in human T lymphocytes.
J Exp Med.
1995;181:71-77 49. Brunner T, Mogil RJ, LaFace D, et al. Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas. Nature. 1995;373:441-444[Medline] [Order article via Infotrieve]. 50. Dhein J, Walczak H, Baumler C, Debatin KM, Krammer PH. Autocrine T-cell suicide mediated by APO-1/(Fas/CD95). Nature. 1995;373:438-443[Medline] [Order article via Infotrieve]. 51. Ju ST, Panka DJ, Cui H, et al. Fas (CD95) FasL interactions required for programmed cell death after T-cell activation. Nature. 1995;373:444-448[Medline] [Order article via Infotrieve]. 52. Wesselborg S, Janssen O, Kabelitz D. Induction of activation-driven death (apoptosis) in activated but not resting peripheral blood T cells. J Immunol. 1993;150:4338-4345[Abstract]. 53. Zheng L, Fisher G, Miller RE, Peschon J, Lynch DH, Lenardo MJ. Induction of apoptosis in mature T cells by tumour necrosis factor. Nature. 1995;377:348-351[Medline] [Order article via Infotrieve]. 54. Tucek-Szabo CL, Andjelic S, Lacy E, Elkon KB, Nikolic-Zugic J. Surface T cell Fas receptor/CD95 regulation, in vivo activation, and apoptosis: activation-induced death can occur without Fas receptor. J Immunol. 1996;156:192-200[Abstract]. 55. Ormerod MG, et al. Increased membrane permeability of apoptotic thymocytes: a flow cytometric study. Cytometry. 1993;14:595-602[Medline] [Order article via Infotrieve]. 56. Sun XM, et al. A flow-cytometric method for the separation and quantitation of normal and apoptotic thymocytes. Anal Biochem. 1992;204:351-356[Medline] [Order article via Infotrieve]. 57. Telford WG, King LE, Fraker PJ. Comparative evaluation of several DNA binding dyes in the detection of apoptosis-associated chromatin degradation by flow cytometry. Cytometry. 1992;13:137-143[Medline] [Order article via Infotrieve]. 58. Gorczyca W, Melamed MR, Darzynkiewicz Z. Analysis of apoptosis by flow cytometry. Methods Mol Biol. 1998;91:217-238[Medline] [Order article via Infotrieve]. 59. Darzynkiewicz Z, et al. Cytometry in cell necrobiology: analysis of apoptosis and accidental cell death (necrosis). Cytometry. 1997;27:1-20[Medline] [Order article via Infotrieve]. 60. Gong J, Traganos F, Darzynkiewicz Z. A selective procedure for DNA extraction from apoptotic cells applicable for gel electrophoresis and flow cytometry. Anal Biochem. 1994;218:314-319[Medline] [Order article via Infotrieve]. 61. Darzynkiewicz Z, et al. Features of apoptotic cells measured by flow cytometry. Cytometry. 1992;13:795-808[Medline] [Order article via Infotrieve].
62.
Darzynkiewicz Z, et al.
Cell cycle-specific effects of tumor necrosis factor.
Cancer Res.
1984;44:83-90 63. Reutelingsperger CPM, van Heerde VW. Annexin V, the regulator of phosphatidylserine-catalyzed inflammation and coagulation during apoptosis. Cell Mol Life Sci. 1997;53:527-532[Medline] [Order article via Infotrieve]. 64. Rimon G, et al. Increased surface phosphatidylserine is an early marker of neuronal apoptosis. J Neurosci Res. 1997;48:563-570[Medline] [Order article via Infotrieve]. 65. Vermes I, et al. A novel assay for apoptosis flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled annexin V. J Immunol Methods. 1995;184:39-51[Medline] [Order article via Infotrieve].
66.
Koopman G, et al.
Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis.
Blood.
1994;84:1415-1420 67. Garner DL, Thomas CA. Organelle-specific probe JC-1 identifies membrane potential differences in the mitochondrial function of bovine sperm. Mol Reprod Dev. 1999;53:222-229[Medline] [Order article via Infotrieve]. 68. Reers M, et al. Mitochondrial membrane potential monitored by JC-1 dye. Methods Enzymol. 1995;260:406-417[Medline] [Order article via Infotrieve]. 69. Reers M, Smith TW, Chen LB. J-Aggregate formation of a carbocyanine as a quantitative fluorescent indicator of membrane potential. Biochemistry. 1991;30:4480-4486[Medline] [Order article via Infotrieve].
70.
Smiley ST, Reers M, Mottola-Hartshorn C, et al.
Intracellular heterogeneity in mitochondrial membrane potentials revealed by a J-aggregate-forming lipophilic cation JC-1.
Proc Natl Acad Sci U S A.
1991;88:3671-3675 71. Gorman AM, et al. Use of flow cytometry techniques in studying mechanisms of apoptosis in leukemic cells. Cytometry. 1997;29:97-105[Medline] [Order article via Infotrieve]. 72. Salvioli S, et al. JC-1, but not DiOC6 (3) or Rhodamine 123, is a reliable fluorescent probe to assess psi changes in intact cells: implications for studies on mitochondrial functionality during apoptosis. FEBS Lett. 1997;411:77-82[Medline] [Order article via Infotrieve]. 73. Kuhnel JM, et al. Functional assay of multidrug resistant cells using JC-1, a carbocyanine fluorescent probe. Leukemia. 1997;11:1147-1155[Medline] [Order article via Infotrieve].
74.
Quillet-Mary A, et al.
Implication of mitochondrial hydrogen peroxide generation in ceramide-induced apoptosis.
J Biol Chem.
1997;272:21388-21395
75.
Herrmann M, et al.
A rapid and simple method for the isolation of apoptotic DNA fragments.
Nucleic Acids Res.
1994;22:5506-5507 76. Walker PR, et al. Detection of the initial stages of DNA fragmentation in apoptosis. BioTechniques. 1993;15:1032-1040[Medline] [Order article via Infotrieve].
77.
Olive PL, Wlodek D, Banath JP.
DNA double-strand breaks measured in individual cells subjected to gel electrophoresis.
Cancer Res.
1991;51:4671-4676 78. Arends MJ, Morris RG, Wyllie AH. Apoptosis: the role of the endonuclease. Am J Pathol. 1990;136:593-608[Abstract]. 79. Singh NP, Stephens RE, Schneider EL. Modifications of alkaline microgel electrophoresis for sensitive detection of DNA damage. Int J Radiat Biol. 1994;66:23-28[Medline] [Order article via Infotrieve]. 80. Singh NP, et al. A simple technique for quantitation of low levels of DNA damage in individual cells. Exp Cell Res. 1988;175:184-191[Medline] [Order article via Infotrieve]. 81. Chapman RS, et al. Further characterization of the in situ terminal deoxynucleotidyl transferase (TdT) assay for the flow cytometric analysis of apoptosis in drug resistant and drug sensitive leukaemic cells. Cytometry. 1995;20:245-256[Medline] [Order article via Infotrieve]. 82. Bromidge TJ, et al. Adaptation of the TdT assay for semi-quantitative flow cytometric detection of DNA strand breaks. Cytometry. 1995;20:257-260[Medline] [Order article via Infotrieve]. 83. Wijsman JH, et al. A new method to detect apoptosis in paraffin sections: in situ end-labelling of fragmented DNA. Cytochemistry. 1993;41:7-12.
84.
Gavrieli Y, Sherman Y, Ben-Sasson SA.
Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation.
J Cell Biol.
1992;119:493-501 85. Staley K, Blaschke AJ, Chun J. Apoptotic DNA fragmentation is detected by a semiquantitative ligation-mediated PCR of blunt DNA ends. Cell Death Differ. 1997;4:66-75[Medline] [Order article via Infotrieve]. 86. Akasaka K, Ohrui H, Meguro H. Simultaneous determination of hydroperoxide of phosphatidylcholine, cholesterol esters and triacylglycerols by column-switching high-performance liquid chromatography with a post-column detection system. J Chromatogr. 1993;622:153-159[Medline] [Order article via Infotrieve]. 87. Akasaka K, Ohrui H, Meguro H. Normal-phase high-performance liquid chromatography with a fluorimetric postcolumn detection system for lipid hydroperoxides. J Chromatogr. 1993;617:205-211[Medline] [Order article via Infotrieve]. 88. Akasaka K, et al. High-performance liquid chromatography and post-column derivatization with diphenyl-1-pyrenylphosphine for fluorimetric determination of triacylglycerol hydroperoxides. J Chromatogr. 1992;596:197-202[Medline] [Order article via Infotrieve]. 89. Akasaka K, Ohrui H, Meguro H. An aromatic phosphine reagent for the HPLC-fluorescence determination of hydroperoxides-determination of phosphatidylcholine hydroperoxides in human plasma. Anal Lett. 1988;21:965. 90. Thornberry NA, et al. Method for use of AFC-120 (Z-TYR-VAL-ALA-ASP-AFC) in determination of ICE and ICE-like enzyme activity. Nature. 1992;356:768-774[Medline] [Order article via Infotrieve]. 91. Garcia-Calvo M, Peterson EP, Rasper DM, Vaillancourt JP, Zamboni-Nicholson DW, Thornberry NA. Purification and catalytic properties of human caspase family members. Cell Death Differ. 1999;6:362-369[Medline] [Order article via Infotrieve].
92.
Thornberry NA, et al.
Method for assay of caspase-8 with AFC-140 (Ac-Ile-Glu-Thr-Asp-AFC).
J Biol Chem.
1997;272:17907-17911 93. Eriksson C, Van Dam AM, Lucassen PJ, Bol JG, Winblad B, Schultzberg M. Immunohistochemical localization of interleukin-1beta, interleukin-1 receptor antagonist and interleukin-1beta converting enzyme/caspase-1 in the rat brain after peripheral administration of kainic acid. Neuroscience. 1999;93:915-930[Medline] [Order article via Infotrieve]. 94. Boyer PD, Chance B, Ernster L, Mitchell P, Racker E, Slater EC. Oxidative phosphorylation and photophosphorylation. Annu Rev Biochem. 1977;46:955-1026[Medline] [Order article via Infotrieve]. 95. Liu X, Kim CN, Yang J, Jemmerson R, Wang R. Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell. 1996;86:147-157[Medline] [Order article via Infotrieve]. 96. Jemmerson R, Johnson JG, Burrell E, Taylor PS, Jenkins MK. A monoclonal antibody specific for a cytochrome c T cell stimulatory peptide inhibits T cell response and affects the way the peptide associates with antigen-presenting cells. Eur J Immunol. 1991;21:143-151[Medline] [Order article via Infotrieve].
97.
Goshorn SC, Retzel E, Jemmerson R.
Common structural features among monoclonal antibodies binding to the same antigenic region of cytochrome c.
J Biol Chem.
1991;266:2134-2142
98.
Narayanan PK, Goodwin EH, Lehnert BE.
99. Rothe G, Valet G. Flow cytometric analysis of respiratory burst activity in phagocytes with hydroethidine and 2',7'- dichlorofluorescin. J Leukoc Biol. 1990;47:440-448[Abstract]. 100. McCloskey TW, Chavan S, Lakshmi-Tamma SM, Pahwa S. Comparison of seven quantitative assays to assess lymphocyte cell death during HIV infection: measurement of induced apoptosis in anti-Fas-treated Jurkat cells and spontaneous apoptosis in peripheral blood mononuclear cells from children infected with HIV. AIDS Res Hum Retroviruses. 1998;14:1413-1422[Medline] [Order article via Infotrieve].
101.
Kaplan D, Sieg S.
Role of the Fas/Fas Ligand apoptotic pathway in human immunodeficiency virus type 1 disease.
J Virol.
1998;72:6279-6282 102. Badley AD, McElhinny JA, Leibson PJ, Lynch DH, Alderson MR, Paya CV. Upregulation of Fas ligand expression by human immunodeficiency virus in human macrophages mediates apoptosis of uninfected T lymphocytes. J Virol. 1996;70:199-206[Abstract]. 103. Virk A, Badley AD, Frigas EA, Harmsen WS, Wiesner RH, Paya CV. Bcl-2 and related proteins are selectively modified by HIV infection prior to virus induced apoptotic cell death. In: Program and abstracts of the XI International Conference on AIDS; July 7-12, 1996; Vancouver, British Columbia. Abstract 143. 104. Mathew P, Badley AD, McElhinny JA, Leibson PJ, Paya CV. Modulation of bcl-2 expression in HIV infected U937 cells. Presented at: 2nd National Conference on Human Retroviruses and Related Infections; January 1995; Washington, DC. Abstract 437. 105. Noraz N, Gozlan J, Corbeil J, Brunner T, Spector SA. HIV-induced apoptosis of activated primary CD4+ T lymphocytes is not mediated by Fas-Fas ligand. AIDS. 1997;11:1671-1680[Medline] [Order article via Infotrieve].
106.
Gandhi RT, Chen BK, Straus SE, Dale JK, Lenardo MJ, Baltimore D.
HIV-1 directly kills CD4+ T cells by a Fas-independent mechanism.
J Exp Med.
1998;187:1113-1122 107. Glynn JM, McElligott DL, Mosier D. Apoptosis induced by HIV infection in H9 T cells is blocked by ICE-family protease inhibition but not by a Fas (CD95) antagonist. J Immunol. 1996;157:2754-2758[Abstract]. 108. Yagi T, Sugimoto A, Tanaka M, et al. Fas/FasL interaction is not involved in apoptosis of activated CD4+ cells upon HIV-1 infection in vitro. AIDS Res Hum Retroviruses. 1998;18:307-315. 109. Regamey N, Harr T, Battegay M, Erb P. Downregulation of Bcl-2, but not of Bax or Bcl-x, is associated with T lymphocyte apoptosis in HIV infection and restored by antiretroviral thearpy or by interleukin 2. AIDS Res Hum Retroviruses. 1999;15:803-810[Medline] [Order article via Infotrieve].
110.
Debatin KM, Fahrig-Faissner A, Enenkel-Stoodt S, Kreuz W, Benner A, Krammer PH.
High expression of APO-1 (CD95) on T lymphocytes from human immunodeficiency virus-1 infected children.
Blood.
1994;83:3101-3103
111.
Katsikis PD, Wunderlich ES, Smith CA, Herzenberg LA, Herzenberg LA.
Fas antigen stimulation induces marked apoptosis of T lymphocytes in human immunodeficiency virus-infected individuals.
J Exp Med.
1995;181:2029-2036 112. McCloskey TW, Oyaizu N, Kaplan M, Pahwa S. Expression of the Fas antigen in patients infected with human immunodeficiency virus. Cytometry. 1995;22:111-114[Medline] [Order article via Infotrieve].
113.
Estaquier J, Tanaka M, Suda T, Nagata S, Golstein P, Ameisen JC.
Fas-mediated apoptosis of CD4+ and CD8+ T cells from human immunodeficiency virus-infected persons: differential in vitro preventive effect of cytokines and protease antagonists.
Blood.
1996;87:4959-4966
114.
Sloand EM, Young NS, Kumar P, Weichold FF, Sato T, Maciejewski JP.
Role of Fas ligand and receptor in the mechanism of T-cell depletion in acquired immunodeficiency syndrome: effect on CD4+ lymphocyte depletion and human immunodeficiency virus replication.
Blood.
1997;89:1357-1363 115. Gehri R, Hahn S, Rothen M, Steurerwald M, Nuesch R, Erb P. The Fas receptor in HIV infection: expression on peripheral blood lymphocytes and role in the depletion of T cells. AIDS. 1996;10:9-16[Medline] [Order article via Infotrieve].
116.
Kobayashi N, Hamamoto Y, Yamamoto N, Ishii A, Yonehara M, Yonehara S.
Anti-Fas monoclonal antibody is cytocidal to human immunodeficiency virus-infected cells without augmenting viral replication.
Proc Natl Acad Sci U S A.
1990;87:9620-9624 117. McCloskey TW, Oyaizu N, Bakshi S, Kowalski R, Kohn N, Pahwa S. CD95 expression and apoptosis during pediatric HIV infection: early upregulation of CD95 expression. Clin Immunol Immunopathol. 1998;87:33-41[Medline] [Order article via Infotrieve]. 118. Mitra D, Steiner M, Lynch DH, Staiano-Coico L, Laurence J. HIV-1 upregulates Fas ligand expression in CD4+ T cells in vitro and in vivo: association with Fas-mediated apoptosis and modulation by aurintricarboxylic acid. Immunology. 1996;87:581-585[Medline] [Order article via Infotrieve]. 119. Silvetris F, Camarda G, Cafforio P, Dammacco F. Upregulation of Fas ligand secretion in non-lymphopenic stages of HIV-1 infection. AIDS. 1998;12:1103-1118[Medline] [Order article via Infotrieve]. 120. Hosaka N, Oyaizu N, Kaplan MH, Yagita H, Pahwa S. Membrane and soluble forms of Fas (CD95) and Fas ligand in peripheral blood mononuclear cells and in plasma from human immunodeficiency virus-infected persons. Infect Dis. 1998;178:1030-1039.
121.
McCloskey TW, Bakshi S, Than S, Arman P, Pahwa S.
Immunophenotypic analysis of peripheral blood mononuclear cells undergoing in vitro apoptosis after isolation from human immunodeficiency virus-infected children.
Blood.
1998;92:4230-4237
122.
Ledru E, Lecoeur H, Garcia S, Debord T, Gougeon ML.
Differential susceptibility to activation-induced apoptosis among peripheral Th1 subsets: correlation with Bcl-2 expression and consequences for AIDS pathogenesis.
J Immunol.
1998;160:3194-3206 123. Szondy Z, Lecoeur H, Fesus L, Gougeon ML. All-trans retinoic acid inhibition of anti-CD3-induced T cell apoptosis in human immunodeficiency virus infection mostly concerns CD4 T lymphocytes and is mediated via regulation of CD95 ligand expression. J Infect Dis. 1998;178:1288-1298[Medline] [Order article via Infotrieve].
124.
Katsikis PD, Garcia-Ojeda ME, Wunderlich ES, et al.
Activation-induced peripheral blood T cell apoptosis is Fas independent in HIV-infected individuals.
Int Immunol.
1996;8:1311-1317 125. Badley AD, Parato K, Cameron DW, et al. Dynamic correlation of apoptosis and immune activation during treatment of HIV infection. Cell Death Differ. 1999;6:420-432[Medline] [Order article via Infotrieve]. 126. Zangerle R, Gallati H, Sarcletti M, Watchter H, Fuchs D. Tumor necrosis factor alpha and soluble tumor necrosis factor receptors in individuals with human immunodeficiency virus infection. Immunol Lett. 1994;41:229-234[Medline] [Order article via Infotrieve]. 127. Chollet-Martin S, Simon F, Matheron S, Joseph CA, Elbim C, Gougerot-Pocidalo MA. Comparison of plasma cytokine levels in African patients with HIV-1 and HIV-2 infection. AIDS. 1994;8:879-884[Medline] [Order article via Infotrieve]. 128. Brown CC, Poli G, Lubaki N, et al. Elevated levels of tumor necrosis factor-alpha in Zairian neonates plasmas: implications for perinatal infection with the human immunodeficiency virus. J Infect Dis. 1994;169:975-980[Medline] [Order article via Infotrieve]. 129. Ayehunie S, Sonnerborg A, Yemane-Berhan T, Zewdie DW, Britton S, Strannegard O. Raised levels of tumor necrosis factor-alpha and neopterin, but not interferon-alpha, in serum of HIV-1 infected patients from Ethiopia. Clin Exp Immunol. 1993;91:37-42[Medline] [Order article via Infotrieve].
130.
Ruddle NH.
Tumor necrosis factor (TNF-
131.
Schwandner R, Wiegmann K, Bernardo K, Kreder D, Kronket M.
TNF receptor death domain-associated proteins TRADD and FADD signal activation of acid sphingomyelinase.
J Biol Chem.
1998;273:5916-5922
132.
Baxter GT, Kuo RC, Jupp OJ, Vandenabeele P, MacEwan DJ.
Tumor necrosis factor- 133. Hober D, Haque A, Wattre P. Production of tumour necrosis factor-alpha and interleukin-1 in patients with AIDS: enhanced TNF-alpha is related to a higher cytotoxic activity. Clin Exp Immunol. 1989;78:329-333[Medline] [Order article via Infotrieve]. 134. Maury CPJ, Lahdevirta J. Correlation of serum cytokine levels with haematological abnormalities in human immunodeficiency virus infection. J Intern Med. 1990;227:253-257[Medline] [Order article via Infotrieve].
135.
Poli G, Kinter A, Justement JS.
Tumour necrosis factor
136.
Vyakarnam A, McKeating J, Meager A, Beverley PC.
Tumour necrosis factors (
137.
Osborn L, Kunkel S, Nabel GJ.
Tumor necrosis factor
138.
Han X, Becker K, Degen HJ, Jablonowski H, Strohmeyer G.
Synergistic stimulatory effects of tumour necrosis factor
139.
Bilello JA, Stellrecht K, Drusano GL, Stein DS.
Soluble tumor necrosis factor-
140.
Badley AD, Dockrell D, Simpson M, et al.
Macrophage-dependent apoptosis of CD4+ T lymphocytes from HIV-infected individuals is mediated by FasL and tumor necrosis factor.
J Exp Med.
1997;185:55-64
141.
Moreira AL, Sampaio EP, Zmuidzinas A.
Thalodomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation.
J Exp Med.
1993;177:1675-1680 142. Dezube BJ, Pardee AB, Chapman B. Pentoxifylline decreases tumor necrosis factor expression and serum triglycerides in people with AIDS. J Acquir Immune Defic Syndr. 1993;6:787-794. 143. Luke DR, McCreedy BJ, Sarnoski TP. Phase I/II study of pentoxyfylline with zidovudine on HIV-1 growth in AIDS patients. Int J Clin Pharmacol Ther Toxicol. 1993;31:343-350[Medline] [Order article via Infotrieve]. 144. Youle M, Clarbour J, Farthing C. Treatment of resistant aphthous ulceration with thalidomide in AIDS. BMJ. 1989;298:432.
145.
Walker RE, Spooner KM, Kelly G, et al.
Inhibition of immunoreactive tumor necrosis factor- 146. French LE, Tschopp J. The TRAIL to selective tumor death. Nature. 1999;5:146-147.
147.
Emery JG, McDonnell P, Burke MB, et al.
Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL.
J Biol Chem.
1998;273:14363-14367 148. Degli-Esposti MA, Dougall WC, Smolak PJ, Waugh JY, Smith CA, Goodwin RG. The novel receptor TRAIL-R4 induces NF-kB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity. 1997;7:813-820[Medline] [Order article via Infotrieve].
149.
Sheridan JP, Marsters SA, Pitti RM, et al.
Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors.
Science.
1997;277:818-821 150. Sedger LM, Shows DM, Blanton RA, et al. IFN-gamma mediates a novel antiviral activity through dynamic modulation of TRAIL and TRAIL receptor expression. Immunology. 1999;163:920-926.
151.
Bretz JD, Rymaszewski M, Arscott PL, et al.
TRAIL death pathway expression and induction in thyroid follicular cells.
J Biol Chem.
1999;274:23627-23632
152.
Griffith TS, Chin WA, Jackson GC, Lynch DH, Kubin MZ.
Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells.
J Immunol.
1998;161:2833-2840 153. Jeremias I, Herr I, Boehler T, Debatin KM. TRAIL/Apo-2-ligand-induced apoptosis in human T cells. Eur J Immunol. 1998;28:143-152[Medline] [Order article via Infotrieve].
154.
Katsikis PD, Garcia-Ojeda ME, Torres-Roca JF, et al.
Interleukin-1# converting enzyme-like protease involvement in Fas-induced and activation-induced peripheral blood T cell apoptosis in HIV infection: TNF-related apoptosis-inducing ligand can mediate activation-induced T cell death in HIV infection.
J Exp Med.
1997;186:1365-1372 155. Banda NK, Bernier J, Kurahara DK, et al. Crosslinking CD4 by human immunodeficiency virus gp120 primes T cells for activation-induced apoptosis. J Exp Med. 1992;76:1099-1106.
156.
Accornero P, Radrizzani M, Delia D, Gerosa F, Kurrle R, Colombo MP.
Differential susceptibility to HIV-GP120-sensitized apoptosis in CD4+ T-cell clones with different T-helper phenotypes: role of CD95/CD95L interactions.
Blood.
1997;89:558-569
157.
Oyaizu N, McCloskey TW, Than S, Hu R, Kalyanaraman VS, Pahwa S.
Cross linking of CD4 molecules upregulates Fas antigen expression in lymphocytes by inducing interferon-
158.
Hashimoto F, Oyaizu N, Kalyanaraman VS, Pahwa S.
Modulation of Bcl-2 protein by CD4 cross-linking: a possible mechanism for lymphocyte apoptosis in human immunodeficiency virus infection and for rescue of apoptosis by interleukin-2.
Blood.
1997;90:745-753
159.
Cicala C, Arthos J, Rubbert A, et al.
HIV-1 envelope induces activation of caspase-3 and cleavage of focal adhesion kinase in primary human CD4 (+) T cells.
Proc Natl Acad Sci U S A.
2000;97:1178-1183 160. Laurent-Crawford AG, Krust B, Riviere Y, et al. Membrane expression of HIV envelope glycoproteins triggers apoptosis in CD4 cells. AIDS Res Hum Retroviruses. 1993;9:761-773[Medline] [Order article via Infotrieve]. 161. Laurent-Crawford AG, Coccia E, Krust B, Hovanessian AG. Membrane-expressed HIV envelope glycoprotein heterodimer is a powerful inducer of cell death in uninfected CD4+ target cells. Res Virol. 1995;146:5-17[Medline] [Order article via Infotrieve].
162.
Moutouh L, Estaquier J, Richman DD, Corbeil J.
Molecular and cellular analysis of human immunodeficiency virus-induced apoptosis in lymphoblastoid T-cell-line-expressing wild-type and mutated CD4 receptors.
J Virol.
1998;72:8061-8072
163.
Guillerm C, Coudronniere N, Robert-Hebmann V, Devaux C.
Delayed human immunodeficiency virus type 1-induced apoptosis in cells expressing truncated forms of CD4.
J Virol.
1997;72:1754-1761
164.
Berndt C, Mopps B, Angermuller S, Gierschik P, Krammer PH.
CXCR4 and CD4 mediate a rapid CD95-independent cell death in CD4+ T cells.
Proc Natl Acad Sci U S A.
1998;95:12556-12561 165. Ohnimus H, Heinkelein M, Jassoy C. Apoptotic cell death upon contact of CD4 T lymphocytes with HIV glycoprotein expressing cells is mediated by caspases but bypasses CD95 (Fas/APO-1) and TNF receptor 1. J Immunol. 1997;159:5246-5252[Abstract]. 166. Blanco J, Jacotot E, Cabrera C, et al. The implication of the chemokine receptor CXCR4 in HIV-1 envelope protein-induced apoptosis is independent of the G protein-mediated signalling. AIDS. 1999;13:909-917[Medline] [Order article via Infotrieve].
167.
Blanco J, Barretina J, Henson G, et al.
The CXCR4 antagonist AMD3100 efficiently inhibits cell-surface-expressed human immunodeficiency virus type 1 envelope-induced apoptosis.
Antimicrob Agents Chemother.
2000;44:51-56 168. Kameoka M, Kimura T, Zheng YH, et al. Protease-defective, gp120-containing human immunodeficiency virus type 1 particles induce apoptosis more efficiently than does wild-type virus or recombinant gp120 protein in healthy donor-derived peripheral blood T cells. J Clin Microbiol. 1997;35:41-47[Abstract]. 169. Ellaurie M, Calvelli TA, Rubinstein A. Human Immunodeficiency virus (HIV) circulating immune complexes in infected children. AIDS Res Hum Retroviruses. 1990;6:1437-1441[Medline] [Order article via Infotrieve]. 170. Aceituno E, Castanon S, Jimenez C, et al. Circulating immune complexes from HIV-1 patients induces apoptosis on normal lymphocytes. Immunology. 1997;92:317-320[Medline] [Order article via Infotrieve].
171.
Bartz SR, Emerman M.
Human immunodeficiency virus type 1 Tat induces apoptosis and increases sensitivity to apoptotic signals by up-regulating FLICE/Caspase-8.
J Virol.
1999;73:1956-1963 172. Li-Weber M, Laur O, Dern K, Krammer PH. T cell activation-induced and HIV tat-enhanced CD95 (APO-1/Fas) ligand transcription involves NF-kB. Eur J Immunol. 2000;30:661-670[Medline] [Order article via Infotrieve].
173.
Li CJ, Friedman DJ, Wang C, Metelev V, Pardee AB.
Induction of apoptosis in uninfected lymphocytes by HIV-1 Tat protein.
Science.
1995;268:429-431 174. Westendorp MO, Frank R, Ochsenbauer K, et al. Sensitization of T cells to CD95-mediated apoptosis by HIV-1 Tat and gp120. Nature. 1995;375:497-500[Medline] [Order article via Infotrieve]. 175. Westendorp MO, Shatrov VA, Schulze-Osthoff K, et al. HIV-1 Tat potentiates TNF-induced NF-kB activation and cytotoxicity by altering the cellular redox state. EMBO J. 1995;14:546-554[Medline] [Order article via Infotrieve]. 176. Chang HC, Samaniego F, Nair BC, Buonaguro L, Ensoli B. HIV-1 Tat protein exits from cells via a leaderless secretory pathway and binds to extracellular matrix-associated heparan sulfate proteoglycans through its basic region. AIDS. 1997;11:1421-1431[Medline] [Order article via Infotrieve].
177.
Gallo RC.
Tat as one key to HIV-induced immune pathogenesis and Pat toxoid as an important component of a vaccine.
Proc Natl Acad Sci U S A.
1999;96:8324-8326 178. Azad AA. Could Nef and Vpr proteins contribute to disease progression by promoting depletion of bystander cells and prolonged survival of HIV-infected cells? Biochem Biophys Res Comm. 2000;267:677-685[Medline] [Order article via Infotrieve].
179.
Kirchhoff F, Greenough TC, Brettler DB, Sullivan JL, Desrosiers RC.
Brief report: absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection.
N Engl J Med.
1995;332:228-232 180. Huang Y, Zhang L, Ho DD. Characterization of nef sequences in long-term survivors of human immunodeficiency virus type 1 infection. J Virol. 1995;69:93-100[Abstract].
181.
Cheng-Mayer C, Iannello P, Shaw K, Luciw PA, Levy JA.
Differential effects of nef on HIV replication: implications for viral pathogenesis in the host.
Science.
1989;246:1629-1632
182.
Niederman TMJ, Thielan BJ, Ratner L.
Human immunodeficiency virus type 1 negative factor is a transcriptional silencer.
Proc Natl Acad Sci U S A.
1989;86:1128-1132
183.
Terwilliger EF, Sodroski JG, Rosen CA, Haseltine WA.
Effects of mutations with the 3'-open reading frame region of human T-cell lymphotropic virus type III (HTLV-III/LAV) on replication and cytopathogenicity.
J Virol.
1986;60:754-760 184. Kestler HW III, Ringler DJ, Mori K, et al. Importance of the nef gene for maintenance of high virus loads and for development of AIDS. Cell. 1991;65:651-662[Medline] [Order article via Infotrieve]. 185. Rhee SS, Marsh JW. HIV-1 Nef Activity in murine T cells: CD4 modulation and positive enhancement. J Immunol. 1994;152:5128-5134[Abstract]. 186. Alexander L, Du Z, Rosenzweig M, Jung JU, Desrosiers RC. A role for natural simian immunodeficiency virus and human immunodeficiency virus type 1 nef alleles in lymphocyte activation. J Virol. 1997;71:6094-6099[Abstract].
187.
Schrager JA, Marsh JW.
HIV-1 Nef increases T cell activation in a stimulus-dependent manner.
Proc Natl Acad Sci U S A.
1999;96:8167-8172
188.
Luria S, Chambers I, Berg P.
Expression of the type 1 human immunodeficiency virus Nef protein in T cells prevents antigen receptor-mediated induction of interleukin 2 mRNA.
Proc Natl Acad Sci U S A.
1991;88:5326-5330
189.
Niederman TM, Garcia JV, Hastings WR, Luria S, Ratner L.
Human immunodeficiency virus type 1 Nef protein inhibits NF-k B induction in human T cells.
J Virol.
1992;66:6213-6219 190. Iafrate AJ, Bronson S, Skowronski J. Separable functions of Nef disrupt two aspects of T cells receptor machinery: CD4 expression and CD3 signaling. EMBO J. 1997;16:673-684[Medline] [Order article via Infotrieve]. 191. Greenway A, Azad A, McPhee D. Human immunodeficiency virus type 1 Nef protein inhibits activation pathways in peripheral blood mononuclear cells and T-cell lines. J Virol. 1995;69:1842-1850[Abstract].
192.
Zauli G, Gibellini D, Secchiero P, et al.
Human immunodeficiency virus type 1 Nef protein sensitizes CD4+ T lymphoid cells to apoptosis via functional upregulation of the CD95/CD95 ligand pathway.
Blood.
1999;93:1000-1010
193.
Xu XN, Screaton GR, Gotch FM, et al.
Evasion of cytotoxic T lymphocyte (CTL) responses by Nef-dependent induction of Fas ligand (CD95L) expression on simian immunodeficiency virus-infected cells.
J Exp Med.
1997;186:7-16
194.
Salghetti S, Mariani R, Skowronski J.
Human immunodeficiency virus type 1 Nef and p56lck protein-tyrosine kinase interact with a common element in CD4 cytoplasmic tail.
Proc Natl Acad Sci U S A.
1995;92:349-353 195. Otake K, Fujii Y, Nakaya T, et al. The carboxyl-terminal region of HIV-1 Nef protein is a cell surface domain that can interact with CD4+ T cells. J Immunol. 1994;153:5826-5837[Abstract]. 196. Okada H, Takei R, Tashiro M. HIV-1 Nef protein-induced apoptotic cytolysis of a broad spectrum of uninfected human blood cells independently of CD95(Fas). FEBS Lett. 1997;414:603-606[Medline] [Order article via Infotrieve]. 197. Stewart SA, Poon B, Jowett JBM, Chen ISY. Human immunodeficiency virus type 1 vpr induces apoptosis following cell cycle arrest. J Virol. 1997;71:5579-5592[Abstract].
198.
Yao X-J, Mouland AJ, Subbramanian RA, et al.
Vpr stimulates viral expression and induces cell killing in human immunodeficiency virus type 1-infected dividing Jurkat T cells.
J Virol.
1998;72:4686-4693
199.
Jacotot E, Ravagnan L, Loeffler M, et al.
The HIV-1 viral protein R induces apoptosis via a direct effect on the mitochondrial permeability transition pore.
J Exp Med.
2000;191:33-45 200. Connor RI, Chen BK, Choe S, Landau NR. Vpr is required for efficient replication of human immunodeficiency virus type 1 in mononuclear phagocytes. Virology. 1995;206:936-944. 201. Levy DN, Rafaeli Y, Weiner DB. Extracellular vpr protein increases cellular permissiveness to human immunodeficiency virus replication and reactivates virus from latency. J Virol. 1995;69:1243-1252[Abstract]. 202. Levy DN. Induction of cell differentiation by human immunodeficiency virus 1 vpr. Cell. 1993;72:541-550[Medline] [Order article via Infotrieve]. 203. He J. Human immunodeficiency virus type 1 protein R (vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity. J Virol. 1995;69:6705-6711[Abstract].
204.
Conti L, Rainaldi G, Matarrese P, et al.
The HIV-1 vpr protein acts as a negative regulator of apoptosis in a human lymphoblastoid T cell line: possible implications for the pathogenesis of AIDS.
J Exp Med.
1998;187:403-413 205. Fukumori T, Akari H, Iida S, et al. The HIV-1 vpr displays strong anti-apoptotic activity. FEBS Lett. 1998;432:17-20[Medline] [Order article via Infotrieve]. 206. Ayyavoo V, Mahboubi A, Mahalingam S, et al. HIV-1 vpr suppresses immune activation and apoptosis through regulation of nuclear factor kB. Nat Med. 1997;3:1117-1123[Medline] [Order article via Infotrieve].
207.
Hrimech M, Yao X-J, Bachand F, Rougeau N, Cohen EA.
Human immunodeficiency virus type 1 (HIV-1) vpr functions as an immediate-early protein during HIV-1 infection.
J Virol.
1999;73:4101-4109
208.
Poon B, Grovit-Ferbas K, Stewart SA, Chen ISY.
Cell cycle arrest by vpr in HIV-1 virions and insensitivity to antiretroviral agents.
Science.
1998;281:266-269 209. Adams LD, Tomasselli AG, Robbins P, Moss P, Heinrikson RL. HIV-1 protease cleaves actin during acute infection human T-lymphocytes. AIDS Res Hum Retroviruses. 1992;8:291-295[Medline] [Order article via Infotrieve]. 210. Buttner J, Dornmair K, Schramm HJ. Screening of inhibitors of HIV-1 protease using an Escherichia coli cell assay. Biochem Biophy Res Comm. 1997;233:36-38[Medline] [Order article via Infotrieve]. 211. Konvalinka J, Litterst MA, Welker R, et al. An active site mutation in the HIV type 1 proteinase (PR) causes reduced PR activity and loss of PR mediated cytotoxicity without apparent effect on virus maturation and infectivity. J Virol. 1995;69:7180-7186[Abstract]. 212. Rivière Y, Blank V, Kourilsky P, Israel A. Processing of the precursor of NF-k B by the HIV-1 protease during acute infection. Nature. 1991;350:625-626[Medline] [Order article via Infotrieve]. 213. Oyaizu N, Adachi Y, Hashimoto F, et al. Monocytes express Fas ligand upon CD4 cross-linking and induce CD4+ T cells apoptosis. J Immunol. 1997;158:2456-2463[Abstract]. 214. Phenix BN, Beckett B, Alam A, et al. HIV protease induces apoptosis of HIV infected T cells through activation of caspase 8. Eighth Annual Canadian Conference of HIV/AIDS Research; 1999; Victoria, British Columbia. Abstract 409.
215.
Strack PR, West Frey M, Rizzo CJ, et al.
Apoptosis mediated by HIV protease is preceded by cleavage of Bcl-2.
Proc Natl Acad Sci U S A.
1996;93:9571-9576
216.
Meyaard L, Otto SA, Jonker RR, Mijnster MJ, Keet RP, Miedema F.
Programmed death of T cells in HIV-1 infection.
Science.
1992;257:217-219
217.
Oyaizu N, McCloskey TW, Coronesi M, Chirmule N, Kalyanaraman VS, Pahwa S.
Accelerated apoptosis in peripheral blood mononuclear cells (PBMCs) from human immunodeficiency virus type-1 infected patients and in CD4 cross-linked PBMCs from normal individuals.
Blood.
1993;82:3392-3400
218.
Groux H, Torpier G, Monte D, Mouton Y, Capron A, Ameisen JC.
Activation-induced death by apoptosis in CD4+ T cells from human immunodeficiency virus-infected asymptomatic individuals.
J Exp Med.
1992;175:331-340
219.
Estaquier J, Idziorek T, Zou W, et al.
T helper type 1/T helper type 2 cytokines and T cell death; preventive effect of interleukin 12 on activation-induced and CD95 (Fas/APO-1)-mediated apoptosis of CD4+ T cells from human immunodeficiency virus-infected persons.
J Exp Med.
1995;182:1759-1767
220.
Alderson MR, Armitage RJ, Maraskovsky E, et al.
Fas transduces activation signals in normal human T lymphocytes.
J Exp Med.
1993;178:2231-2235
221.
Yang Y, Mercep M, Ware CF, Ashwell JD.
Fas and activation-induced Fas ligand mediate apoptosis of T cell hybridomas: inhibition of Fas ligand expression by retinoic acid and glucocorticoids.
J Exp Med.
1995;181:1673-1682
222.
Meuer SC, Hodgdon JC, Hussey RE, Protentis JP, Schlossman SF, Reinherz EL.
Antigen-like effects of monoclonal antibodies directed at receptors on human T cell clones.
J Exp Med.
1983;158:988-993 223. Nau GJ, Kim D-K, Fitch FW. Agents that mimic antigen receptor signalling inhibit proliferation of cloned murine T lymphocytes induced by Il-2. J Immunol. 1988;141:3557-3563[Abstract]. 224. Breitmeyer JB, Oppenheim SO, Delay JF, Levine HB, Schlossman SF. Growth inhibition of human T cells by antibodies recognizing the T cell antigen receptor complex. J Immunol. 1987;138:726-731[Abstract].
225.
Webb S, Sprent J.
Downregulation of T cell responses by antibodies to the T cell receptor.
J Exp Med.
1987;165:584-589 226. Mercep M, Bluestone JA, Noguchi PD, Ashwell JD. Inhibition of transformed T cell growth by monoclonal antibodies directed against distinct activating molecules. J Immunol. 1988;140:324-335[Abstract]. 227. Gougeon ML, Lecoeur H, Dulioust A, et al. Programmed cell death in peripheral lymphocytes from HIV-infected persons: increased susceptibility to apoptosis of CD4 and CD8 T cells correlates with lymphocyte activation and with disease progression. J Immunol. 1996;156:3509-3520[Abstract]. 228. Miedema F, Petit AJ, Terpstra FG, et al. Immunological abnormalities in human immunodeficiency virus (HIV)-infected asymptomatic homosexual men: HIV affects the immune system before CD4+ T cell deletion occurs. J Clin Invest. 1988;82:1908-1914. 229. Clerici M, Hakim F, Venzon D, et al. Changes in interleukin-2 and interleukin-4 production in asymptomatic human immunodeficiency virus-seropositive individuals. J Clin Invest. 1993;91:759-765. 230. Graziosi C, Pantaleo G, Fauci AS. Comparative analysis of constitutive cytokine expression in peripheral blood and lymph nodes of HIV-infected individuals. Res Immunol. 1994;145:602-605[Medline] [Order article via Infotrieve].
231.
Meyaard L, Otto SA, Keet IP, van Lier RA, Miedema F.
Changes in cytokine secretion patterns of CD4+ T-cell clones in human immunodeficiency virus infection.
Blood.
1994;84:4262-4268 232. Aries SP, Schaaf B, Muller C, Dennin RH, Dalhoff K. Fas (CD95) expression on CD4+ T cells from HIV-infected patients increases with disease progression. J Mol Med. 1995;73:591-593[Medline] [Order article via Infotrieve]. 233. Silvestris F, Cafforio P, Frassanito MA, et al. Overexpression of Fas antigen on T cells in advanced HIV-1 infection: differential ligation constantly induces apoptosis. AIDS. 1996;10:131-141[Medline] [Order article via Infotrieve].
234.
Baumler CB, Bohler T, Herr R, Benner A, Krammer PH, Debatin KM.
Activation of the CD95 (APO-1/Fas) system in T cells from human immunodeficiency virus type-1 infected children.
Blood.
1996;88:1741-1746
235.
Yang Y, Bailey J, Vacchio MS, Yarchoan R, Ashwell JD.
Retinoic acid inhibition of ex vivo human immunodeficiency virus-associated apoptosis of peripheral blood cells.
Proc Natl Acad Sci U S A.
1995;92:3051-3055 236. Sarin A, Clerici M, Blatt SP, Hendrix CW, Shearer GM, Henkart PA. Inhibition of activation-induced programmed cell death and restoration of defective immune responses of HIV+ donors by cysteine protease inhibitors. J Immunol. 1994;153:862-872[Abstract]. 237. Dockrell DH, Badley AD, Algeciras-Schimnich A, et al. Activation-induced CD4 T cell death in HIV positive individuals correlates with Fas-susceptibility, CD4 T cell count and HIV plasma viral copy number. AIDS Res Hum Retro. 1999;15:1509-1518[Medline] [Order article via Infotrieve]. 238. Cottrez F, Manca F, Dalgleish AG, Arenzana-Seisdedos F, Capron A, Groux H. Priming of human CD4+ antigen-specific T cells to undergo apoptosis by HIV-infected monocytes. J Clin Invest. 1997;99:257-266[Medline] [Order article via Infotrieve]. 239. Orlikowsky T, Wang Z-Q, Dudhane A, Horowitz H, Riethmuller G, Hoffman MK. Cytotoxic monocytes in the blood of HIV type-1 infected subjects destroy targeted T cells in a CD-95-dependent fashion. AIDS Res Hum Retroviruses. 1997;13:953-960[Medline] [Order article via Infotrieve].
240.
Nardelli B, Gonzalez CJ, Schechter M, Valentine FT.
CD4+ blood lymphocytes are rapidly killed in vitro by contact with autologous human immunodeficiency virus-infected cells.
Proc Natl Acad Sci U S A.
1995;92:7312-7316
241.
Kameoka M, Suzuki S, Kimura T, et al.
Exposure of resting peripheral blood T cells to HIV-1 particles generates CD25+ killer cells in a small subset, leading to induction of apoptosis in bystander cells.
Int Immunol.
1997;9:1453-1462 242. Kojima H, Eshima K, Takayama H, Sitkovsky MV. Leukocyte function-associated antigen-1 dependent lysis of Fas+ (CD95+/Apo-1+) innocent bystanders by antigen-specific CD8+ CTL. J Immunol. 1997;158:2728-2734. 243. Lewis DE, Ng Tang DS, Wang X, Kozinetz C. Costimulatory pathways mediate monocyte-dependent lymphocyte apoptosis in HIV. Clin Immunol. 1999;90:302-312[Medline] [Order article via Infotrieve].
244.
Herbein G, Van Lint C, Lovett JL, Verdin E.
Distinct mechanisms trigger apoptosis in human immunodeficiency virus type-1 infected and in uninfected bystander T lymphocytes.
J Virol.
1998;72:660-670 245. Dockrell DH, Badley AD, Villacian JS, et al. The expression of Fas ligand by macrophages and its upregulation by human immunodeficiency virus infection. J Clin Invest. 1998;101:2394-2405[Medline] [Order article via Infotrieve].
246.
Hadida F, Vieillard V, Mollet L, Clark-Lewis I, Baggiolini M, Debre P.
Cutting edge: RANTES regulates Fas ligand expression and killing by HIV-specific CD8 cytotoxic T cells.
J Immunol.
1999;163:1105-1109
247.
Lauener RP, Hüttner S, Buisson M, et al.
T-cell death by apoptosis in vertically human immunodeficiency virus-infected children coincides with expansion of CD8+/interleukin-2 receptor-/HLA-DR+ T cells: sign of a possible role for herpes viruses as cofactors?
Blood.
1995;86:1400-1407 248. Lewis DE, Ng Tang DS, Adu-Oppong A, Schober W, Rodgers JR. Anergy and apoptosis in CD8+ T cells from HIV-infected persons. J Immunol. 1994;153:412-420[Abstract]. 249. Meyaard L, Otto SA, Keet IPM, Roos MTL, Miedema F. Programmed death of T cells in human immunodeficiency virus infection: no correlation with progression to disease. J Clin Invest. 1994;93:982-988. 250. Fultz PN, Schwiebert RS, Su L, Salter MM. Effects of total lymphoid irradiation on SIV-infected macaques. AIDS Res Hum Retroviruses. 1995;11:1517-1527[Medline] [Order article via Infotrieve].
251.
Hakim FT, Cepeda R, Kaimei S, et al.
Constraints on CD4 recovery postchemotherapy in adults: thymic insufficiency and apoptotic decline of expanded peripheral CD4 cells.
Blood.
1997;90:3789-3798 252. Gratama JW, Lipovich-Oosterveer MA, Willemze R, et al. Reduction and repopulation of T-lymphocytes after cytoreductive therapy with or without autologous bone marrow rescue. Exp Hematol. 1986;14:173-177[Medline] [Order article via Infotrieve]. 253. Herbein G, Mahlknecht U, Batliwalla F, et al. Apoptosis of CD8+ T cells is mediated by macrophages through interaction of HIV gp120 with chemokine receptor CXCR4. Nature. 1998;395:189-194[Medline] [Order article via Infotrieve]. 254. Giorgi JV, Detels R. T-cell subset alterations in HIV-infected homosexual men: NIAID multicenter AIDs cohort study. Clin Immunol Immunopathol. 1989;52:10-18[Medline] [Order article via Infotrieve]. 255. Giorgi JV, Liu Z, Hultin LE, Cumberland WG, Hennessen K, Detels R. Elevated levels of CD38+CD8+ cells in HIV infection add to the prognostic value of low CD4+ T cell levels: results of 6 years follow-up. J Acquir Immune Defic Syndr. 1993;6:904-912. 256. Giorgi JV, Ho HN, Hirji K, et al. CD8+ lymphocyte activation at human immunodeficiency virus type 1 seroconversion: development of HLA-DR+CD38-CD8+ cells is associated with subsequent stable CD4+ cell levels. J Infect Dis. 1994;170:775-781[Medline] [Order article via Infotrieve]. 257. Levacher M, Hulstaert F, Tallet S, Ullery S, Pocidalo JJ, Bach BA. The significance of activation markers on CD8 lymphocytes in human immunodeficiency syndrome: staging and prognostic value. Clin Exp Immunol. 1992;90:376-382[Medline] [Order article via Infotrieve].
258.
Flamand L, Crowley RW, Lusso P, Colombini-Hatch S, Margolis DM, Gallo RC.
Activation of CD8+ T lymphocytes through the T cell receptor turns on CD4 gene expression: implications for HIV pathogenesis.
Proc Natl Acad Sci U S A.
1998;95:3111-3116
259.
Yang LP, Riley JL, Carroll RG, et al.
Productive infection of neonatal CD8+ T lymphocytes by HIV-1.
J Exp Med.
1998;187:1139-1144 260. Finkel TH, Tudor-Williams G, Banda NK, et al. Apoptosis occurs predominantly in bystander cells and not in productively infected cells of HIV- and SIV- infected lymph nodes. Nat Med. 1995;1:129-134[Medline] [Order article via Infotrieve]. 261. Røsok B, Brinchmann JE, Stent G, et al. Correlates of apoptosis of CD4+ and CD8+ T cells in tonsillar tissue in HIV Type 1 infection. AIDS Res Hum Retroviruses. 1998;14:1635-1643[Medline] [Order article via Infotrieve]. 262. Muro-Cacho CA, Pantaleo G, Fauci A. Analysis of apoptosis in lymph nodes of HIV-1 infected persons: intensity of apoptosis correlates with the general state of activatin of the lymphoid tissue and not with stage of disease or viral burden. J Immunol. 1995;154:5555-5566[Abstract]. 263. Patki AH, Georges DL, Lederman MM. CD4+-T-cell counts, spontaneous apoptosis, and Fas expression in peripheral blood mononuclear cells obtained from human immunodeficiency virus type 1-infected subjects. Clin Diagn Lab Immunol. 1997;4:736-741[Abstract]. 264. Prati E, Gorla R, Malacarne F, et al. Study of spontaneous apoptosis in HIV + patients: correlation with clinical progression and T cell loss. AIDS Res Hum Retroviruses. 1997;13:1501-1508[Medline] [Order article via Infotrieve]. 265. Samuelsson A, Broström C, Van Dijk N, Sönnerborg A, Chiodi F. Apoptosis of CD4+ and CD19+ cells during human immunodeficiency virus type 1 infection: correlation with clinical progression, viral load, and loss of humoral immunity. Virology. 1997;238:180-188[Medline] [Order article via Infotrieve]. 266. Liegler TJ, Yonemoto W, Elbeik T, Wittinghoff E, Buchbinder SP, Greene WC. Diminished spontaneous apoptosis in lymphocytes from human immunodeficiency virus-infected long-term nonprogressors. J Infect Dis. 1998;178:669-679[Medline] [Order article via Infotrieve]. 267. Wasmuth JC, Klein KH, Hackbarth F, Rockstroh JK, Sauerbruch T, Spengler U. Prediction of imminent complications in HIV-1-infected patients by markers of lymphocyte apoptosis. J Acquir Immune Defic Syndr. 2000;23:44-51. 268. Franceschi C, Franceschini MG, Boschini A, et al. Phenotypic characteristics and tendency to apoptosis of peripheral blood mononuclear cells from HIV+ long term non progressors. Cell Death Differ. 1997;4:815-823. 269. Chavan SJ, Tamma SL, Kaplan M, Gerstein M, Pahwa SG. Reduction in T cell apoptosis in patients with HIV disease following antiretroviral therapy. Clin Immunol. 1999;93:24-33[Medline] [Order article via Infotrieve]. 270. Kotler DP, Shimada T, Snow G, et al. Effect of combination antiretroviral therapy upon rectal mucosal HIV RNA burden and mononuclear cell apoptosis. AIDS. 1998;12:597-604[Medline] [Order article via Infotrieve]. 271. Johnson N, Parkin JM. Anti-retroviral therapy reverses HIV-associated abnormalities in lymphocyte apoptosis. Clin Exp Immunol. 1998;113:229-234[Medline] [Order article via Infotrieve]. 272. Aries SP, Weyrich K, Schaaf B, Hansen F, Dennin RH, Dalhoff K. Early T-cell apoptosis and Fas expression during antiretroviral therapy in individuals infected with human immunodeficiency virus-1. Scand J Immunol. 1998;48:86-91[Medline] [Order article via Infotrieve]. 273. Badley AD, Dockrell DH, Algeciras A, et al. In vivo analysis of Fas/FasL interactions in HIV-infected patients. J Clin Invest. 1998;102:79-87[Medline] [Order article via Infotrieve]. 274. Böhler T, Walcher J, Hölzl-Wenig G, et al. Early effects of antiretroviral combination therapy on activation, apoptosis and regeneration of T cells in HIV-1 infected children and adolescents. AIDS. 1999;13:779-789[Medline] [Order article via Infotrieve].
275.
Sloand EM, Kumar PN, Kim S, Chaudhuri A, Weichold FF, Young NS.
Human immunodeficiency virus type 1 protease inhibitor modulates activation of peripheral blood CD4+ T cells and decreases their susceptibility to apoptosis in vitro and in vivo.
Blood.
1999;94:1021-1027 276. Phenix BN, Angel JB, Mandy F, et al. Decreased HIV-associated T cell apoptosis by HIV protease inhibitors. AIDS Res Hum Retroviruses. 2000;16:559-567[Medline] [Order article via Infotrieve]. 277. Clerici M, Shearer GM. A TH1 to TH2 switch is a critical step in the etiology of HIV infection. Immunol Today. 1993;14:107-111[Medline] [Order article via Infotrieve].
278.
Clerici M, Lucey DR, Berzofsky JA, et al.
Restoration of HIV-specific cell-mediated immune response by IL-12 in vitro.
Science.
1993;262:1721-1724 279. Clerici M, Lucey DR, Berzofsky JA, et al. Role of IL-10 in T helper cell dysfunction in asymptomatic individuals infected with HIV. J Clin Invest. 1994;93:768-775.
280.
Clerici M, Sarin A, Coffman RL, et al.
Type 1/type 2 cytokine modulation of T cell programmed cell death as a model for HIV pathogenesis.
Proc Natl Acad Sci U S A.
1994;91:11811-11815 281. Gougeon ML, Garcia S, Heeney J, et al. Programmed cell death in AIDS-related HIV and SIV infections. AIDS Res Hum Retroviruses. 1993;9:553-563[Medline] [Order article via Infotrieve]. 282. Clerici M, Sarin A, Berzofsky JA, et al. Antigen-stimulated apoptotic T-cell death in HIV infection is selective for CD4+ T cells, modulated by cytokines and effected by lymphotoxin. AIDS. 1996;10:603-611[Medline] [Order article via Infotrieve]. 283. Adachi Y, Oyaizu N, Than S, McCloskey TW, Pahwa S. IL-2 Rescues in vitro lymphocyte apoptosis in patients with HIV infection. J Immunol. 1996;157:4184-4193[Abstract]. 284. Cosman D, Kumaki S, Anderson D, Kennedy M, Eisenman J, Park L. Interleukin 15. Biochem Soc Trans. 1997;25:371-374[Medline] [Order article via Infotrieve]. 285. Lucey DR, Pinto LA, Bethke FR, et al. In vitro immunologic and virologic effects of interleukin 15 on peripheral blood mononuclear cells from normal donors and human immunodeficiency virus type-1 infected patients. Clin Diagn Lab Immunol. 1997;4:43-48[Abstract].
286.
Agostini C, Trentin L, Sancetta R, et al.
Interleukin-15 triggers activation and growth of the CD8 T-cell pool in extravascular tissues of patients with acquired immunodeficiency syndrome.
Blood.
1997;90:1115-1123 287. Patki AH, QuiOones-Mateu ME, Dorazio D, et al. Activation of antigen-induced lymphocyte proliferation by Interleukin-15 without the mitogenic effect of Interleukin-2 that may induce human immunodeficiency virus-1 expression. J Clin Invest. 1996;98:616-621[Medline] [Order article via Infotrieve]. 288. Chehimi J, Marshall JD, Salvucci O, et al. IL-15 enhances immune functions during HIV infection. J Immunol. 1997;158:5978-5987[Abstract]. 289. Center DM, Kornfeld H, Cruikshank WW. Interleukin-16 and function as a CD4 ligand. Immunol Today. 1996;17:476-481[Medline] [Order article via Infotrieve]. 290. Cruikshank WW, Lim K, Theodore AC, et al. IL-16 inhibition of CD3-dependent lymphocyte activation and proliferation. J Immunol. 1996;157:5240-5248[Abstract]. 291. Baier M, Werner A, Bannert N, Metzner K, Kurth R. HIV suppression by interleukin-16. Nature. 1995;378:563[Medline] [Order article via Infotrieve]. 292. Idziorek T, Khalife J, Billaut-Mulot O, et al. Recombinant human IL-16 inhibits HIV-1 replication and protects against activation-induced cell death (AICD). Clin Exp Immunol. 1998;112:84-91[Medline] [Order article via Infotrieve]. 293. Bucy RP, Hockett RD, Derdeyn CA, et al. Initial increase in blood CD4+ lymphocytes after HIV antiretroviral therapy reflects redistribution from lymphoid tissues. J Clin Invest. 1999;103:1391-1398[Medline] [Order article via Infotrieve]. 294. Fleury S, De Boer RJ, Rizzardi GP, et al. Limited CD4+ T-cell renewal in early HIV-1 infection: effect of highly active antiretroviral therapy. Nat Med. 1998;4:794-801[Medline] [Order article via Infotrieve].
295.
Zhang L, Lewin SR, Markowitz M, et al.
Measuring recent thymic emigrants in blood of normal and HIV-1 infected individuals before and after effective therapy.
J Exp Med.
1999;190:725-732
296.
Poulin JF, Viswanathan MN, Harris JM, et al.
Direct evidence for thymic function in adult humans.
J Exp Med.
1999;190:479-486 297. Weichold FF, Bryant JL, Pati S, Barabitskaya O, Gallo RC, Reitz MSJ. HIV-1 protease inhibitor ritonavir modulates susceptibility to apoptosis of uninfected T cells. J Hum Virol. 1999;2:261-269[Medline] [Order article via Infotrieve].
298.
Collier AC, Coombs RW, Schoenfeld DA.
Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine.
N Engl J Med.
1996;334:1011-1017 299. Kaufmann D, Pantaleo G, Sudre P, Telenti A. CD4-cell count in HIV-1 infected individuals remaining viraemic with highly active antiretroviral therapy (HAART). Lancet. 1998;351:723-724[Medline] [Order article via Infotrieve].
300.
Levitz SM.
Improvement in CD4+ cell counts despite persistently detectable HIV load.
N Engl J Med.
1998;338:1074-1075 301. Piketty C, Castiel P, Belec L. Discrepant responses to triple combination antiretroviral therapy in advanced HIV disease. AIDS. 1998;12:745-750[Medline] [Order article via Infotrieve]. 302. Mezzaroma I, Carlesimo M, Pinter E, et al. Long-term evaluation of T-cell subsets and T-cell function after HAART in advanced stage HIV-1 disease. AIDS. 1999;13:1187-1193[Medline] [Order article via Infotrieve]. 303. Li TS, Tubiana R, Katlama C, Calvez V, Ait Mohand H, Autran B. Long-lasting recovery in CD4 T-cell function and viral-load reduction after highly active antiretroviral therapy in advanced HIV-1 disease. Lancet. 1998;351:1682-1686[Medline] [Order article via Infotrieve]. 304. Lederman MM, Connick E, Landay A, et al. Immunologic responses associated with 12 weeks of combination antiretroviral therapy consisting of zidovudine, lamivudine, and ritonavir: results of AIDS Clinical Trials Group Protocol 315. J Infect Dis. 1998;178:70-79[Medline] [Order article via Infotrieve]. 305. Pakker NG, Roos MT, van Leeuwen R, et al. Patterns of T-cell repopulation, virus load reduction, and restoration of T-cell function in HIV-infected persons during therapy with different antiretroviral agents. J Acquir Immune Defic Syndr. 1997;16:318-326. 306. Angel JB, Kumar A, Parato K, et al. Improvement in cell-mediated immune function during potent anti-human immunodeficiency virus therapy with ritonavir plus saquinavir. J Infect Dis. 1998;177:898-904[Medline] [Order article via Infotrieve].
307.
Sousa AE, Chaves AF, Doroana M, Antunes F, Victorino RMM.
Kinetics of the changes of lymphocyte subsets defined by cytokine production at single cell level during highly active antiretroviral therapy for HIV-1 infection.
J Immunol.
1999;162:3718-3726 308. Chinnaiyan AM, Woffendin C, Dixit VM, Nabel GJ. The inhibition of pro-apoptotic ICE-like proteases enhances HIV replication. Nat Med. 1997;3:333-337[Medline] [Order article via Infotrieve].
309.
Chun TW, Fauci AS.
Latent reservoirs of HIV: obstacles to the eradication of virus.
Proc Natl Acad Sci U S A.
1999;96:10958-10961
310.
Schrager LK, D'Souza MP.
Cellular and anatomical reservoirs of HIV-1 in patients receiving potent antiretroviral combination therapy.
JAMA.
1998;280:67-71 311. Finzi D, Blankson J, Siliciano JD, et al. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat Med. 1999;5:512-517[Medline] [Order article via Infotrieve].
312.
Ho DD.
Toward HIV eradication or remission: the tasks ahead.
Science.
1998;280:1866-1867 313. Wein LM, D'Amato RM, Perelson AS. Mathematical analysis of antiretroviral therapy aimed at HIV-1 eradication or maintenance of low viral loads. J Theor Biol. 1998;192:81-98[Medline] [Order article via Infotrieve].
314.
Zhang L, Ramratnam B, Tenner-Racz K.
Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy.
N Engl J Med.
1999;340:1605-1613 315. Vocero-Akbani AM, Heyden NV, Lissy NA, Ratner L, Dowdy SF. Killing HIV-infected cells by transduction with an HIV protease-activated caspase-3 protein. Nat Med. 1999;5:29-33[Medline] [Order article via Infotrieve].
© 2000 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  M. S. Giri, M. Nebozyhn, A. Raymond, B. Gekonge, A. Hancock, S. Creer, C. Nicols, M. Yousef, A. S. Foulkes, K. Mounzer, et al. Circulating Monocytes in HIV-1-Infected Viremic Subjects Exhibit an Antiapoptosis Gene Signature and Virus- and Host-Mediated Apoptosis Resistance J. Immunol., April 1, 2009; 182(7): 4459 - 4470. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Noursadeghi, J. Tsang, R. F. Miller, S. Straschewski, P. Kellam, B. M. Chain, and D. R. Katz Genome-Wide Innate Immune Responses in HIV-1-Infected Macrophages Are Preserved Despite Attenuation of the NF-{kappa}B Activation Pathway J. Immunol., January 1, 2009; 182(1): 319 - 328. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Gasper-Smith, D. M. Crossman, J. F. Whitesides, N. Mensali, J. S. Ottinger, S. G. Plonk, M. A. Moody, G. Ferrari, K. J. Weinhold, S. E. Miller, et al. Induction of Plasma (TRAIL), TNFR-2, Fas Ligand, and Plasma Microparticles after Human Immunodeficiency Virus Type 1 (HIV-1) Transmission: Implications for HIV-1 Vaccine Design J. Virol., August 1, 2008; 82(15): 7700 - 7710. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Noursadeghi, J. Tsang, R. F. Miller, and D. R. Katz Comment on "Transcription Factor FOXO3a Mediates Apoptosis in HIV-1-Infected Macrophages" J. Immunol., June 15, 2008; 180(12): 7783 - 7783. [Full Text] [PDF]
|
|
|
|
|
|
R. M. Dunham, B. Cervasi, J. M. Brenchley, H. Albrecht, A. Weintrob, B. Sumpter, J. Engram, S. Gordon, N. R. Klatt, I. Frank, et al. CD127 and CD25 Expression Defines CD4+ T Cell Subsets That Are Differentially Depleted during HIV Infection J. Immunol., April 15, 2008; 180(8): 5582 - 5592. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Biancotto, J.-C. Grivel, S. J. Iglehart, C. Vanpouille, A. Lisco, S. F. Sieg, R. Debernardo, K. Garate, B. Rodriguez, L. B. Margolis, et al. Abnormal activation and cytokine spectra in lymph nodes of people chronically infected with HIV-1 Blood, May 15, 2007; 109(10): 4272 - 4279. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Fluur, A. De Milito, T. J. Fry, N. Vivar, L. Eidsmo, A. Atlas, C. Federici, P. Matarrese, M. Logozzi, E. Rajnavolgyi, et al. Potential Role for IL-7 in Fas-Mediated T Cell Apoptosis During HIV Infection J. Immunol., April 15, 2007; 178(8): 5340 - 5350. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Petrovas, Y. M. Mueller, I. D. Dimitriou, S. R. Altork, A. Banerjee, P. Sklar, K. C. Mounzer, J. D. Altman, and P. D. Katsikis Increased mitochondrial mass characterizes the survival defect of HIV-specific CD8+ T cells Blood, March 15, 2007; 109(6): 2505 - 2513. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Viollet, V. Monceaux, F. Petit, R. H. T. Fang, M.-C. Cumont, B. Hurtrel, and J. Estaquier Death of CD4+ T Cells from Lymph Nodes during Primary SIVmac251 Infection Predicts the Rate of AIDS Progression J. Immunol., November 15, 2006; 177(10): 6685 - 6694. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. L. Fanning, T. C. George, D. Feng, S. B. Feldman, N. J. Megjugorac, A. G. Izaguirre, and P. Fitzgerald-Bocarsly Receptor Cross-Linking on Human Plasmacytoid Dendritic Cells Leads to the Regulation of IFN-{alpha} Production J. Immunol., November 1, 2006; 177(9): 5829 - 5839. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. R. Anand and R. K. Ganju HIV-1 gp120-mediated Apoptosis of T Cells Is Regulated by the Membrane Tyrosine Phosphatase CD45 J. Biol. Chem., May 5, 2006; 281(18): 12289 - 12299. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Paiardini, B. Cervasi, B. Sumpter, H. M. McClure, D. L. Sodora, M. Magnani, S. I. Staprans, G. Piedimonte, and G. Silvestri Perturbations of Cell Cycle Control in T Cells Contribute to the Different Outcomes of Simian Immunodeficiency Virus Infection in Rhesus Macaques and Sooty Mangabeys J. Virol., January 15, 2006; 80(2): 634 - 642. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Zaunders, M. L. Munier, D. E. Kaufmann, S. Ip, P. Grey, D. Smith, T. Ramacciotti, D. Quan, R. Finlayson, J. Kaldor, et al. Early proliferation of CCR5+ CD38+++ antigen-specific CD4+ Th1 effector cells during primary HIV-1 infection Blood, September 1, 2005; 106(5): 1660 - 1667. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Ross, S. Martinka, V. D. D'Agati, and L. A. Bruggeman NF-{kappa}B Regulates Fas-Mediated Apoptosis in HIV-Associated Nephropathy J. Am. Soc. Nephrol., August 1, 2005; 16(8): 2403 - 2411. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Aukrust, L. Luna, T. Ueland, R. F. Johansen, F. Muller, S. S. Froland, E. C. Seeberg, and M. Bjoras Impaired base excision repair and accumulation of oxidative base lesions in CD4+ T cells of HIV-infected patients Blood, June 15, 2005; 105(12): 4730 - 4735. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Priceputu, I. Rodrigue, P. Chrobak, J. Poudrier, T. W. Mak, Z. Hanna, C. Hu, D. G. Kay, and P. Jolicoeur The Nef-Mediated AIDS-Like Disease of CD4C/Human Immunodeficiency Virus Transgenic Mice Is Associated with Increased Fas/FasL Expression on T Cells and T-Cell Death but Is Not Prevented in Fas-, FasL-, Tumor Necrosis Factor Receptor 1-, or Interleukin-1{beta}-Converting Enzyme-Deficient or Bcl2-Expressing Transgenic Mice J. Virol., May 15, 2005; 79(10): 6377 - 6391. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Gulow, M. Kaminski, K. Darvas, D. Suss, M. Li-Weber, and P. H. Krammer HIV-1 Trans-Activator of Transcription Substitutes for Oxidative Signaling in Activation-Induced T Cell Death J. Immunol., May 1, 2005; 174(9): 5249 - 5260. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Eidsmo, S. Nylen, A. Khamesipour, M.-A. Hedblad, F. Chiodi, and H. Akuffo The Contribution of the Fas/FasL Apoptotic Pathway in Ulcer Formation during Leishmania major-Induced Cutaneous Leishmaniasis Am. J. Pathol., April 1, 2005; 166(4): 1099 - 1108. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P.-O. Vidalain On the TRAIL of HIV-induced immunosuppression Blood, March 15, 2005; 105(6): 2241 - 2241. [Full Text] [PDF]
|
|
|
|
|
|
J.-P. Herbeuval, A. Boasso, J.-C. Grivel, A. W. Hardy, S. A. Anderson, M. J. Dolan, C. Chougnet, J. D. Lifson, and G. M. Shearer TNF-related apoptosis-inducing ligand (TRAIL) in HIV-1-infected patients and its in vitro production by antigen-presenting cells Blood, March 15, 2005; 105(6): 2458 - 2464. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J.-L. Perfettini, M. Castedo, R. Nardacci, F. Ciccosanti, P. Boya, T. Roumier, N. Larochette, M. Piacentini, and G. Kroemer Essential role of p53 phosphorylation by p38 MAPK in apoptosis induction by the HIV-1 envelope J. Exp. Med., January 18, 2005; 201(2): 279 - 289. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Perez, M. Inman, A. Doster, and C. Jones Latency-Related Gene Encoded by Bovine Herpesvirus 1 Promotes Virus Growth and Reactivation from Latency in Tonsils of Infected Calves J. Clin. Microbiol., January 1, 2005; 43(1): 393 - 401. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Andreau, J.-L. Perfettini, M. Castedo, D. Metivier, V. Scott, G. Pierron, and G. Kroemer Contagious apoptosis facilitated by the HIV-1 envelope: fusion-induced cell-to-cell transmission of a lethal signal J. Cell Sci., November 1, 2004; 117(23): 5643 - 5653. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Blanco, J. Barretina, B. Clotet, and J. A. Este R5 HIV gp120-mediated cellular contacts induce the death of single CCR5-expressing CD4 T cells by a gp41-dependent mechanism J. Leukoc. Biol., October 1, 2004; 76(4): 804 - 811. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Torgler, S. Jakob, E. Ontsouka, U. Nachbur, C. Mueller, D. R. Green, and T. Brunner Regulation of Activation-induced Fas (CD95/Apo-1) Ligand Expression in T Cells by the Cyclin B1/Cdk1 Complex J. Biol. Chem., September 3, 2004; 279(36): 37334 - 37342. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Maranon, J.-F. Desoutter, G. Hoeffel, W. Cohen, D. Hanau, and A. Hosmalin Dendritic cells cross-present HIV antigens from live as well as apoptotic infected CD4+ T lymphocytes PNAS, April 20, 2004; 101(16): 6092 - 6097. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Grelli, G. d'Ettorre, F. Lauria, F. Montella, L. Di Traglia, M. Lichtner, V. Vullo, C. Favalli, S. Vella, B. Macchi, et al. Inverse correlation between CD8+ lymphocyte apoptosis and CD4+ cell counts during potent antiretroviral therapy in HIV patients J. Antimicrob. Chemother., March 1, 2004; 53(3): 494 - 500. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-L. Perfettini, T. Roumier, M. Castedo, N. Larochette, P. Boya, B. Raynal, V. Lazar, F. Ciccosanti, R. Nardacci, J. Penninger, et al. NF-{kappa}B and p53 Are the Dominant Apoptosis-inducing Transcription Factors Elicited by the HIV-1 Envelope J. Exp. Med., March 1, 2004; 199(5): 629 - 640. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Lanteri, V. Giordanengo, N. Hiraoka, J.-G. Fuzibet, P. Auberger, M. Fukuda, L. G. Baum, and J.-C. Lefebvre Altered T cell surface glycosylation in HIV-1 infection results in increased susceptibility to galectin-1-induced cell death Glycobiology, December 1, 2003; 13(12): 909 - 918. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Komoto, S. Tsuji, M. S. Ibrahim, Y.-G. Li, J. Warachit, K. Taniguchi, and K. Ikuta The Vpu Protein of Human Immunodeficiency Virus Type 1 Plays a Protective Role against Virus-Induced Apoptosis in Primary CD4+ T Lymphocytes J. Virol., October 1, 2003; 77(19): 10304 - 10313. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Monceaux, R. H. T. Fang, M. C. Cumont, B. Hurtrel, and J. Estaquier Distinct Cycling CD4+- and CD8+-T-Cell Profiles during the Asymptomatic Phase of Simian Immunodeficiency Virus SIVmac251 Infection in Rhesus Macaques J. Virol., September 15, 2003; 77(18): 10047 - 10059. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. L. Kinter, C. A. Umscheid, J. Arthos, C. Cicala, Y. Lin, R. Jackson, E. Donoghue, L. Ehler, J. Adelsberger, R. L. Rabin, et al. HIV Envelope Induces Virus Expression from Resting CD4+ T Cells Isolated from HIV-Infected Individuals in the Absence of Markers of Cellular Activation or Apoptosis J. Immunol., March 1, 2003; 170(5): 2449 - 2455. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. R. Lewin, R. M. Ribeiro, G. R. Kaufmann, D. Smith, J. Zaunders, M. Law, A. Solomon, P. U. Cameron, D. Cooper, and A. S. Perelson Dynamics of T Cells and TCR Excision Circles Differ After Treatment of Acute and Chronic HIV Infection J. Immunol., October 15, 2002; 169(8): 4657 - 4666. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X.-Q. Zhao, X.-L. Huang, P. Gupta, L. Borowski, Z. Fan, S. C. Watkins, E. K. Thomas, and C. R. Rinaldo Jr. Induction of Anti-Human Immunodeficiency Virus Type 1 (HIV-1) CD8+ and CD4+ T-Cell Reactivity by Dendritic Cells Loaded with HIV-1 X4-Infected Apoptotic Cells J. Virol., February 22, 2002; 76(6): 3007 - 3014. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. J. J. van der Vliet, B. M. E. von Blomberg, M. D. Hazenberg, N. Nishi, S. A. Otto, B. H. van Benthem, M. Prins, F. A. Claessen, A. J. M. van den Eertwegh, G. Giaccone, et al. Selective Decrease in Circulating V{alpha}24+V{beta}11+ NKT Cells During HIV Type 1 Infection J. Immunol., February 1, 2002; 168(3): 1490 - 1495. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Lum, A. A. Pilon, J. Sanchez-Dardon, B. N. Phenix, J. E. Kim, J. Mihowich, K. Jamison, N. Hawley-Foss, D. H. Lynch, and A. D. Badley Induction of Cell Death in Human Immunodeficiency Virus-Infected Macrophages and Resting Memory CD4 T Cells by TRAIL/Apo2L J. Virol., November 15, 2001; 75(22): 11128 - 11136. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Akari, S. Bour, S. Kao, A. Adachi, and K. Strebel The Human Immunodeficiency Virus Type 1 Accessory Protein Vpu Induces Apoptosis by Suppressing the Nuclear Factor {kappa}B-dependent Expression of Antiapoptotic Factors J. Exp. Med., November 5, 2001; 194(9): 1299 - 1312. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Castedo, K. F. Ferri, J. Blanco, T. Roumier, N. Larochette, J. Barretina, A. Amendola, R. Nardacci, D. Metivier, J. A. Este, et al. Human Immunodeficiency Virus 1 Envelope Glycoprotein Complex-Induced Apoptosis Involves Mammalian Target of Rapamycin/Fkbp12-Rapamycin-Associated Protein-Mediated P53 Phosphorylation J. Exp. Med., October 15, 2001; 194(8): 1097 - 1110. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Secchiero, P. Mirandola, D. Zella, C. Celeghini, A. Gonelli, M. Vitale, S. Capitani, and G. Zauli Human herpesvirus 7 induces the functional up-regulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) coupled to TRAIL-R1 down-modulation in CD4+ T cells Blood, October 15, 2001; 98(8): 2474 - 2481. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. V. Evans, B. P. Wood, J. J. Scarisbrick, E. A. Fraser-Andrews, S. Chinn, A. Dean, P. Watkins, S. J. Whittaker, and R. Russell-Jones Extracorporeal photopheresis in Sezary syndrome: hematologic parameters as predictors of response Blood, September 1, 2001; 98(5): 1298 - 1301. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Basanez and J. Zimmerberg HIV and Apoptosis: Death and the Mitochondrion J. Exp. Med., February 19, 2001; 193(4): f11 - f14. [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2000 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
cells,
Fas, TNF, and TRAIL/APO 2-L
subunit and the shared IL-2R
and IL-2R